Women and Health Initiative working pape by Kendall, Tamil et al.
WOMEN AND HEALTH INITIATIVE WORKING PAPER SERIES 
RESEARCH AND EVALUATION AGENDA FOR
 



















Tamil Kendall is a postdoctoral research fellow with the Women and Health Initiative and a 
Takemi Fellow in International Health at the Harvard School of Public Health. Isabella Danel is 
Chief of the Field Support Branch, Division of Reproductive Health, National Center for Chronic 
Disease Prevention and Health Promotion, Centers for Disease Control and Prevention.
The contents are the responsibility of the authors and do not necessarily reflect the views of 
CDC, OGAC, USAID or the US Government. 
Suggested Citation:  
Kendall, T. and I. Danel (2014). Research and Evaluation Agenda for HIV and Maternal Health 
in sub-Saharan Africa: Women and Health Initiative Working Paper No. 1. Women and Health 
Initiative, Harvard School of Public Health: Boston, MA. http://www.mhtf.org





   
   
   
    
   
   
   
   
   
   
   
   
   
   
   
   
   
  
  
   
   
   
   
   
   
   
   
   
   
   
   
   
  
  
   




   
    




AIDS Acquired immune-deficiency syndrome
ALPHA Analyzing Longitudinal Population-based HIV/AIDS data on Africa
ANC Antenatal care
AOR Adjusted odds ratio
ART Antiretroviral therapy
ARV Antiretroviral (drugs)
CD4 Cluster of differentiation antigen 4
CDC United States Centers for Disease Control and Prevention
CI Confidence interval
CVCT Couple voluntary counseling and testing
DHS Demographic health survey
EFV Efavirenz
FP Family planning
HIV Human immuno-deficiency virus
HSPH Harvard School of Public Health
ICAP International Center for AIDS Care and Treatment Programs
ICD code International classification of diseases
IMAGE Intervention with Microfinance for AIDS and Gender Equity
iMMR Institutional Maternal Mortality Ratio 
InterVA Interpreting Verbal Autopsies 
IPTp Intermittent Preventive Treatment of Malaria in Pregnancy (IPTp) 
IPT Isoniazid preventive therapy
IPV Intimate partner violence
ITN Insecticide treated nets
IRIS Immune Reconstitution Inflammatory Syndrome
IVCT Individual voluntary counseling and testing
M2M Mother to mother
MCH Maternal and child health
MHTF Maternal Health Task Force
MICS Multiple Indicator Cluster Survey
MMR Maternal mortality ratio




PEPFAR United States President’s Emergency Plan for AIDS Relief
PLHIV People living with HIV
PMTCT Prevention of mother to child transmission
PrEP Pre-exposure prophylaxis
RCT Randomized Controlled Trial
RMC Respectful maternity care
Sd-NVP Single dose nevirapine









SP  Sulfadoxine-pyrimethamine 
STI  Sexually Transmitted Infection 
TASO  The AIDS Support Organization  
TB  Tuberculosis 
UN  United Nations 
USAID United States Agency for International Development 
WHO  World Health Organization 















The Research and Evaluation Agenda for Maternal Health and HIV in sub-Saharan Africa
benefited from the collective experience, knowledge, and thoughtful comments of the Advisory 
Group:
Diane Cooper (Women’s Health Research Unit, University of Cape Town) 
 
Sophie Dilmitis (Independent Consultant, Zimbabwe) 
 
Angela Kaida (Simon Fraser University) 
 
Marge Koblinsky (USAID) 
 
Athena P. Kourtis (US Centers for Disease Control and Prevention)
  
Ana Langer (Maternal Health Task Force, Women and Health Initiative, HSPH) 
 
Ilana Lapidos-Salaiz (USAID) 
 
Eva Lathrop (Emory University) 
 
Allisyn Moran (USAID) 
 
Tshidi Hannah Sebitloane (University of Kwazulu Natal) 
 
Janet Turan (University of Alabama at Birmingham) 
 
Heather Watts (Office of the US Global AIDS Coordinator) 
 
Mary Nell Wegner (Maternal Health Task Force, Women and Health Initiative, HSPH) 
 
Speciosa Wandira-Kazibwe offered insightful comments on a draft document. Leilani Hastings 

provided research assistance. Tamil Kendall’s postdoctoral fellowship is supported by the 

Canadian Institutes of Health Research, the Pierre Elliott Trudeau Foundation, and the Women 

and Health Initiative and the Takemi Program in International Health at the Harvard School of 

Public Health. Funding for this work was provided by the US Centers for Disease Control and 

Prevention though an Inter-agency Personnel Agreement with the Harvard School of Public 






   
 
   
   
   
   
   
   
   
   
   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   








Introduction: Maternal Mortality and HIV..............................................................................12
 
HIV and Maternal Mortality: What Do We Know?..................................................................13
 
HIV and Maternal Health: Programmatic Progress and Persistent Gaps ..................................14
 
Priorities for Research and Evaluation ......................................................................................16
 








Research Priority 1: Clinical Questions about Maternal Mortality and HIV .......................25
 
Priority Research Questions ..................................................................................................26
 
Key Outcomes and Variables: ...............................................................................................26
 














Controversies about Iron Supplementation during Pregnancy in Women Infected with or 
































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   










Priority Research Questions ..................................................................................................49
 
Key Outcomes and Variables ................................................................................................49
 












Reproductive Health of Women with HIV: Pre-Conception Counseling and Postpartum 

Contraceptives for HIV-Positive Women..............................................................................55
 








Human Resources Shortages and Workload ........................................................................64
 














Research Priority 3: Transforming the Social Context to Improve Maternal Health..........70
 
Priority Research Questions ..................................................................................................71
 
Key Outcomes and Variables ................................................................................................72
 





















   
   
   
   
   
   
   
   
   
   
 
 












Implications for Policy and Practice..........................................................................................83
 



























                                                
           
          
               
       
Executive Summary
Objectives
In June 2013, a group of international maternal health and HIV researchers came together 
in Boston under the auspices of the Maternal Health Task Force (MHTF) at the Harvard School 
of Public Health, the United States Agency for International Development (USAID), and the 
Centers for Disease Control and Prevention (CDC) to share emerging evidence, identify 
promising practices for scale-up, and develop a priority research agenda.1 Drawing on 
discussions during the “Maternal Health, HIV and AIDS: Examining Research Through A 
Programmatic Lens” meeting and a comprehensive review of the peer-reviewed literature,2 this 
research and evaluation agenda synthesizes existing knowledge and frames priority research 
questions that must be answered to improve maternal health in the context of sub-Saharan 
Africa’s HIV pandemic. The agenda also seeks to provide guidance to researchers, programmers,
and policymakers about how to advance research and evaluation relevant for policy, programs,
and service delivery in the short- and medium-term. 
Maternal Mortality and HIV
Internationally, HIV and complications of childbearing are the top causes of death among 
women of reproductive age. The research and evaluation agenda focuses on sub-Saharan Africa 
because in 2011, 90% of pregnant women with HIV resided there and recent estimates suggest 
that a quarter of deaths during pregnancy and the six week postpartum period in the region are 
attributable to HIV. Transforming the negative synergies between maternal health and HIV into 
opportunities to promote the health and well-being of women of reproductive age is necessary to 
prevent new HIV infections, eliminate AIDS-related deaths, and to end preventable maternal 
mortality. 
Maternal deaths due to non-obstetric causes predominate among women with HIV, and 
those with advanced disease and least time on antiretroviral therapy (ART) face the highest risk 
1 See Annex 1 for the list of individuals who participated in the June 12 2013 meeting with  to develop a research
agenda for maternal health and HIV in sub-Saharan Africa
2 A comprehensive review of the grey literature was not conducted, however information from presentations made at
















of death. Earlier and more widespread access to ART is expected to reduce maternal morbidity 
and mortality, but the impact of ART on causes, rates and distribution of maternal morbidity and 
mortality in low and middle-income countries is not yet well-defined. The need to evaluate the 
health impacts of new HIV treatment guidelines which recommend earlier initiation of treatment 
for all adults, the implementation of programs which seek to initiate all pregnant and 
breastfeeding women on lifelong ART regardless of their immune status (Option B+), and 
recognition of the potential of “treatment as prevention” provide the context for the identified 
research priorities. 
To date, significant advances have been made towards increasing availability of HIV-
testing during pregnancy and provision of ART to prevent mother-to-child transmission 
(PMTCT) of HIV in many high-burden countries. However, insufficient integration of HIV and 
Maternal and Child Health (MCH) services persists and opportunities to improve women’s 
health by addressing tuberculosis, malaria, and reproductive health in HIV and MCH services are 
missed. Furthermore, rates of uptake, linkage between MCH and HIV care, retention and ART 
adherence are suboptimal. Reducing HIV-related stigma and gender discrimination, including 
violence against women, increasing social support for women during pregnancy and the 
extended postpartum period, and mobilizing communities to promote respectful, high quality 
HIV and MCH services are promising interventions for creating an enabling environment for 
women to access and remain in care. Finally, while an exhaustive discussion of human resource 
needs is beyond the substantive scope of this research and evaluation agenda, there is a clear 
need to address human resource shortages in the health systems of sub-Saharan Africa and to 
assess required skills in the context of task-shifting as a prerequisite for improving the coverage 
and quality of integrated MCH and HIV interventions. 
Research Priorities
The third day of the expert meeting was dedicated to developing a consensus research 
agenda. Meeting participants identified the following three priorities: 1) Improve the evidence 
base to better ascertain causes of maternal morbidity and mortality among women with HIV and 
conduct research to assess changes in rates, distribution, and causes of maternal death as ART 
availability is scaled-up; 2) Implement and evaluate integrated HIV and MCH service delivery 








    









tuberculosis and provision of pre-conception counseling and postpartum contraceptives in 
integrated service delivery models; 3) Determine how best to create an enabling environment for 
women to enter and remain in HIV and MCH care by reducing violence against women and 
HIV-related stigma,  mobilizing communities to promote respectful, high-quality MCH and HIV 
services, and increasing social support for women during pregnancy and the extended 
postpartum period, including by involving male partners. 
Moving the Research Agenda Forward
Much of the data needed to answer the key research questions is currently available but 
needs to be analyzed, or could be generated with reasonable investments to enhance program 
monitoring, or to implement intervention research and collect complementary data within the 
context of randomized controlled trials and observational studies. Given the need to optimize 
scarce resources and generate data relevant for policies and programs in the short-term, 
opportunities to answer pressing research questions immediately and in the short-term were 
identified by the meeting participants. Improvement of vital registration, harmonization of data 
collection and inclusion of key indicators by HIV and maternal health programs in monitoring 
and evaluation (including maternal death reviews) are essential to advance the evidence base. 
Conclusions
Improving maternal health in the context of the sub-Saharan African HIV epidemic 
requires greater understanding of the relationships between HIV disease and maternal morbidity 
and mortality, integrated and effective responses by the health system, and a social context which 
promotes quality care and encourages use of MCH and HIV services. Advancing the proposed 
research agenda will make an invaluable contribution by generating needed evidence for policy 
and practice that improves the maternal health of women who are living with HIV, as well as 
those who are not. Bringing together maternal health and HIV researchers, policy-makers and 
program implementers to reduce HIV-related maternal morbidity and mortality and improve the 
HIV response for women represents an opportunity and a challenge. Collaborating on research 
which addresses HIV and maternal health and capturing key outcomes and variables routinely in 
program evaluation and monitoring is one way to raise awareness and catalyze the joint 




















   
Introduction: MaternalMortality and HIV
The two top causes of death in women of reproductive age globally are HIV and AIDS 
(19%) and complications related to childbearing (15%) (WHO 2009). Sub-Saharan Africa is the 
region with the highest maternal mortality rate globally (596 per 100,000 live births) and where 
half of maternal deaths occur (Hogan, Foreman et al. 2010). In 2011, 90% of the total number of 
pregnant women with HIV lived in sub-Saharan Africa (UNAIDS 2012b). The region is home to 
69% of the 34 million people living with HIV globally (UNAIDS 2012a). A recent analysis of 
mortality during pregnancy and the six week postpartum period found that women with HIV 
were eight times more likely to die than their HIV-negative counterparts and led the researchers 
to estimate that a quarter of deaths of pregnant and postpartum women in sub-Saharan Africa are 
attributable to HIV (Zaba, Calvert et al. 2013). Given these findings, the 2012 resolution by the 
UN Commission on the Status of Women to eliminate preventable maternal mortality will not be 
achieved unless HIV among women of reproductive age is addressed and care of pregnant 
women living with HIV is improved (United Nations 2010). Changing the negative synergies 
between HIV and poor maternal health outcomes into opportunities to promote the health and 
well-being of women of reproductive age, both those who are living with HIV and those who are 
not, is an urgent international public health priority.  
This document presents priorities for research and evaluation from the meeting Maternal 
Health, HIV and AIDS: Examining Research Through A Programmatic Lens which brought 
together researchers, programmers and policymakers in Boston, MA June 10-13, 2013 under the 
auspices of the Maternal Health Task Force (MHTF) at the Harvard School of Public Health, the 
United States Agency for International Development (USAID), and the Centers for Disease 
Control and Prevention (CDC). This meeting was one of the first to bring maternal health and 
HIV experts together to have a substantive discussion of the existing evidence and priority 
research gaps in the field of maternal health and HIV in sub-Saharan Africa.  
The meeting participants identified the following three priorities: 1) Improving cause of 
death data to better understand relationships between HIV and maternal morbidity and mortality 
and to assess the impact of scaled-up access to ART on maternal health outcomes; 2) Evaluating 




















tuberculosis, preconception counseling and postpartum contraception services; 3) Creating an 
enabling environment for women to enter and remain in HIV and MCH care. 
Many of the research questions are concerned with identifying how best to implement 
interventions that are known to work (at least in some settings and for some health outcomes) 
and evaluating their impact on the reduction of maternal mortality and improved maternal health 
outcomes in the context of HIV. Some questions can be answered by enhancing routine program 
monitoring and evaluation. Others will require implementation research or the creation of new 
observational cohorts or adding complementary research components to other studies. Meeting 
participants emphasized the need to tailor interventions for the country context and to conduct 
cross-country analysis.
HIV and Maternal Mortality: What Do We Know?
Globally, between 6% and 18% of maternal deaths are attributable to HIV, and women 
living with HIV in sub-Saharan Africa are six to eight times more likely to die than their HIV-
negative counterparts (Hogan, Foreman et al. 2010, Calvert and Ronsmans 2013b, Zaba, Calvert
et al. 2013). Maternal deaths among women with HIV are mostly attributed to indirect rather 
than obstetric causes, particularly non-pregnancy-related infections (Ramogale, Moodley et al. 
2007, Menendez, Romagosa et al. 2008, Moodley and Pattison 2012, Ordi, Ismail et al. 2009, 
Chweneyagae, Delis-Jarrosay et al. 2012). Malaria and tuberculosis pose increased risk of 
morbidity and mortality in pregnancy and these risks are substantially increased when women 
are also living with HIV (Brentlinger, Behrens et al. 2006, Khan, Pillay et al. 2001, Gupta, 
Nayak et al. 2007, ter Kuile, Parise et al. 2004, Ticconi, Mapfumo et al. 2003). Despite the 
predominance of non-obstetric causes of death, women with HIV experience greater mortality 
due to puerperal sepsis and obstetric hemorrhage than their HIV-negative peers (Sebitloane 
2013, Sebitloane, Moodley et al. 2009). At this time, the available data does not allow for the 
quantification of maternal mortality among women in low resource settings who are treated with 
antiretrovirals (ARV) early in pregnancy, nor is it known how increased access to ART will 






















HIV and Maternal Health: Programmatic Progress and Persistent Gaps
Globally, significant progress towards reducing maternal mortality has been made, 
however much remains to be done especially in sub-Saharan Africa. The number of women 
estimated to have died each year from causes related to pregnancy or childbirth has dropped 
substantially from 543,000 deaths in 1990 to around 287,000 deaths in 2010—but eight countries 
in sub-Saharan Africa with high HIV prevalence have experienced increases in maternal 
mortality over the past two decades (WHO and UNICEF 2013). Reductions in maternal deaths 
have largely been attributable to a decline in total fertility rate, increased income per head in 
Asia and Latin America, improved maternal education in sub-Saharan Africa, and increases in 
skilled birth attendance (Hogan, Foreman et al. 2010).  To eliminate preventable maternal 
mortality and respond to HIV among women, it is imperative not to miss the opportunities 
created when women attend health services during the continuum of maternity care (pregnancy, 
delivery, and postpartum) or when they seek HIV care. There is also a need to continue to 
improve quality of care and reduce barriers to women attending HIV and MCH services.
To address HIV during pregnancy for the woman’s health and for PMTCT, knowledge of 
women’s HIV status is necessary. In 2012, only 38% of pregnant women in low and middle 
income countries received HIV counseling and testing (WHO, UNICEF et al. 2013: 61). In 
Africa, 49% of pregnant women were tested for HIV and some sub-Saharan African countries 
with high burdens of HIV disease made great strides towards universal coverage: Botswana, 
Mozambique, South Africa and Zambia all provided HIV testing to 95% of pregnant women
(WHO, UNICEF et al. 2013: 60). In 2011, more than half of pregnant women with HIV in Africa 
(58%) received antiretrovirals for PMTCT; in Eastern and Southern Africa the coverage rate was
71%; and some countries prioritized in the Global Plan to Eliminate Mother-to-Child HIV 
Transmission achieved rates of 80-90% (WHO, UNICEF et al. 2013: 28-30). New treatment 
guidelines which recommend earlier initiation of ART (at a CD4+ cell count of 500 cells/uL 
rather than a CD4+ cell count of 350 cells/uL) and the promotion of programs which seek to 
initiate pregnant and breastfeeding women on lifelong ART independent of women’s immune 
status (Option B+) provide the backdrop for the identified research priorities (WHO 2013a). 
Advances in PMTCT contrast with poor progress in implementing other pillars of the 



















women, preventing unintended pregnancies among women with HIV and providing treatment, 
care, and support to women with HIV and their families (WHO and UNFPA 2006). This 
research and evaluation agenda prioritizes interventions to improve the reproductive health of 
women living with HIV and to increase uptake and retention in MCH and HIV services and 
adherence to ART during pregnancy and beyond.  
Rates of unmet need for family planning remain unacceptably high among women in 
sub-Saharan Africa, including for those living with HIV, even if they are participating in 
treatment programs (Darroch and Singh 2013, Sarnquist, Rahangdale et al. 2013). The potential 
for contraceptives to reduce unintended pregnancies among women living with HIV (and thus 
contribute to PMTCT and reducing maternal morbidity and mortality) is not being realized. 
Similarly, the game-changing potential of antiretroviral treatment to radically reduce sexual 
transmission and to increase reproductive options for people living with HIV and their partners 
needs to be addressed within MCH and HIV care.
Finally, significant programmatic and social barriers must be overcome to ensure that 
HIV diagnosis during prenatal care translates into access to life-saving ART for women and to 
promote uptake, retention, and adherence to HIV and MCH care. While progress has been made 
on the provision of treatment to pregnant women for their own health—jumping from 30% in 
2011 to 58% in 2012—estimates indicate that they are still less likely to benefit than other 
treatment eligible adults (UNAIDS 2012a: 47, UNAIDS 2013: 42). Documented barriers to 
women beginning HIV treatment for PMTCT and for their own health include: lack of 
knowledge about the benefits of ART, psychological factors (such as shock, denial, fear of 
treatment side effects), not having any symptoms of HIV disease, financial constraints and HIV-
related stigma, particularly fears about disclosure, and lack of partner and family support 
(Ferguson, Grant et al. 2012, Gourlay, Birdthistle et al. 2013, Turan and Nyblade 2013). Broader 
health systems issues such as poor quality of care (inadequate skills and availability of staff, 
disrespect and abuse, stock-outs, delays in service provision), and geographic and economic 
barriers are also associated with poor uptake and retention of women in PMTCT and dropping 
out of the treatment cascade and not accessing HIV services, including ART, for themselves 















   
 
                                                
                
     
The focus of this research and evaluation agenda is the health of women living with HIV 
during pregnancy and the extended postpartum period3, with the understanding that maternal 
health is an important component of women’s health and that high-quality, supportive 
interactions with the health system during pregnancy and postpartum can have long-term positive 
consequences for women who are living with HIV as well as those who are not.  Infant and child
health is considered specifically only with respect to how scale-up of ART and consequent 
exposure to ART in utero will affect health outcomes. While the focus of this paper is maternal 
health, the available information strongly suggests that research and evaluation to improve 
service provision for women living with HIV who are not pregnant and men living with HIV are 
also important priorities (WHO, UNICEF et al. 2013, Zaba, Calvert et al. 2013).
Priorities for Research and Evaluation
Knowledge about the relationships between HIV and maternal health is rapidly 
advancing and many aspects of the programmatic response have made impressive progress, but 
big questions remain. Available evidence suggests that pregnancy does not accelerate HIV
disease progression (MacCarthy, Laher et al. 2009). On the other hand, there is evidence that 
women living with HIV have higher rates of maternal morbidity and mortality (Calvert and 
Ronsmans 2013a, Zaba, Calvert et al. 2013). However, it is not clear how much HIV in and of 
itself aggravates pregnancy-related conditions, nor how ART will affect the rates and causes of 
death among pregnant and postpartum women living with HIV. Questions about the complex 
interactions between HIV disease, immune status, time on ART, pregnancy and the postpartum 
period, and the rates, causes and distribution of maternal morbidity and mortality need to be 
answered. Generating evidence about these relationships in the context of rapid treatment scale-
up to provide clinical and programmatic guidance to improve women’s health is the focus of 
Research Priority 1: Clinical Questions about Maternal Mortality and HIV.
Second, the available evidence tends to support integration of services as a way to 
respond to the multiple health needs of pregnant and postpartum women, but questions remain 
about how to best increase coverage without compromising effectiveness of specific 
3 Unless specified as six weeks postpartum, throughout the document postpartum refers to the extended postpartum
















interventions or overwhelming already overburdened health systems and health workers. While 
the clinical effectiveness of PMTCT has been demonstrated in both high and low-income 
countries, there is surprisingly little evidence about the maternal health outcomes of integrating 
ART into antenatal and postpartum care even though countries are moving towards integrating 
HIV with MCH services. Similarly, while some countries have been pioneering integrated 
approaches, little implementation research has been conducted on the integration of other critical
components of care that are needed to promote women’s health and reduce maternal morbidity 
and mortality. Research Priority 2: Integrating Health Service Delivery to Address Maternal 
Health and HIV focuses on evaluating models for effectively integrating MCH and HIV care
with malaria, tuberculosis, and broader sexual and reproductive health (SRH) services, 
particularly preconception counseling and postpartum contraception services. 
Third, relatively poor uptake and retention in MCH and HIV services and suboptimal ART 
adherence, particularly among postpartum women, must be better understood and overcome to 
promote women’s health. To achieve the desired results and truly support the health of women 
and communities, investments in ART scale-up must appropriately address the realities of 
women’s lives, which include gender discrimination and HIV-related stigma. Research Priority 
3: Transforming the Social Context to Improve Maternal Health proposes evaluation of 
interventions which will contribute to an enabling social context and effectively link women to 




     




























                                                
                 
          
           
Summary of Priority Research and Evaluation Questions
Research Priority 1: Clinical Questions about Maternal Mortality and HIV
Priority Research Questions 




•	 How will rates and causes of morbidity and mortality during pregnancy and the 
postpartum period be affected by increased availability of antiretroviral treatment for 
women living with HIV of reproductive age, including provision of lifelong ART to 
pregnant and postpartum women?
Key Outcomes and Variables4 
•	 HIV status, pregnancy/postpartum status, currently on ART, gestational age (or trimester) 
at initiation or on ART at conception, time on ART, ART regimen, CD4 and viral load 
(most recent and at treatment initiation), WHO disease stage, cause of death, causes of 
maternal morbidity, type of delivery (vaginal or cesarean), perinatal outcome (live or 
stillbirth), cost-benefit and cost-effectiveness
Research Priority 2: Integrating Health Service Delivery to Address Maternal Health and 
HIV
Priority Research Questions
•	 What are the most effective models for integrating HIV testing, treatment and care with 
antenatal, intrapartum, and postpartum services?
•	 How can additional critical interventions—specifically screening, prophylaxis and 
treatment for malaria and tuberculosis, postpartum family planning, and preconception 
counseling—be integrated into the continuum of MCH and HIV services while 
maintaining quality, effectiveness and coverage?
Key Outcomes and Variables
•	 Health outcomes: clinical effectiveness of different interventions with integration, 
maternal morbidity and mortality, pediatric HIV infection, and sexual HIV transmission. 
•	 Health systems: national policies and budget allocation, process indicators to assess 
coverage and quality of care (including uptake of MCH and HIV services), satisfaction 
and retention of healthcare workers and service users, human resources needed to 
delivery interventions (ratio and cadre of providers to service users, skill level), cost-
benefit and cost-effectiveness. 
4 Depending on the intervention to be evaluated and the setting, researchers and programmers will need to select and
define specific indicators to measure inputs, process, and outcomes. Validated tools and techniques are mentioned















   





Research Priority 3: Transforming the Social Context to Improve Maternal Health
Priority Research Questions
•	 What are the effects of programs which reduce HIV-related stigma and discrimination, 
disrespect and abuse in maternity care, and violence against women on uptake and 
retention in HIV and MCH services, adherence to ART, disclosure of HIV status, and 
postpartum depression?
•	 How does increasing social support for pregnant and postpartum women, including from 
male partners, and community mobilization to promote respectful, high-quality HIV and 
MCH services affect maternal health outcomes?
Key outcomes and variables 
•	 Uptake of HIV and MCH services, linkage from HIV diagnosis to treatment, retention in 
care, antiretroviral adherence, postpartum depression, disclosure of HIV status, HIV-
related stigma and discrimination, disrespect and abuse in maternity care, other health-
related quality of life measures, cost-benefit and cost-effectiveness.
Conceptual Framework
The three research priorities focus on different levels of the social and programmatic context 
relevant for HIV and maternal health (see Figure 1): Priority 1 addresses the individual woman 
and clinical outcomes; Priority 2 considers interactions between pregnant and postpartum women 
and healthcare providers and the multiple health needs to be addressed within the context of the 
health system; and Priority 3 seeks to assess how interventions which contribute to transforming 
social determinants of health and the broader social context affect women’s uptake of and 
















           






There are mutually influential relationships between the identified Research Priorities and the 
different levels of the health system and social environment where research will be conducted 
and programs implemented. Promoting evidence-based policies and programs will resonate 
positively across all three levels and ultimately improve women’s health at the country level. To 
illustrate, better information about HIV status, antiretroviral regimen and cause of death can 
guide prioritization of interventions in different country and regional contexts, resource 
allocation, and inform healthcare provider training.  Similarly, community monitoring and social 
support (which increase demand for and supply of MCH and HIV services) can increase uptake 
and improve individual ART adherence while acknowledging that individual behavior is shaped 
by social context. These outcomes contribute to better individual health and also to public health 
by reducing sexual HIV transmission, preventing MTCT and slowing the development of 
antiretroviral resistance.  
The Need for Consistent Process and Outcome Measures in HIV and MCH
Research and Programs
Improved data quality and generation of consistent and comparable indicators in HIV and 
MCH services are necessary to monitor and evaluate progress toward reducing maternal 
morbidity, eliminating preventable maternal mortality and addressing the HIV and AIDS 
pandemic among women of reproductive age. Strengthening vital registration and national health 
information systems and collecting key indicators in routine program monitoring and evaluation 
will be essential for generating the needed evidence about maternal health and HIV. At a 
minimum, the HIV status of pregnant women needs to be known, which is in itself a challenge 
given that in 2012 just half of pregnant women in Africa were offered HIV testing (WHO, 
UNICEF et al. 2013). Where possible, disease stage, and markers of immune status (viral load 
and CD4), time on ART, and treatment regimen would be invaluable information for 
understanding the relationship between HIV and maternal deaths. 
In 2012, the World Health Organization published guidance to facilitate the consistent 
coding of maternal death certificates (WHO 2012e). The guidance emphasizes identification of a 




















maternal death (WHO 2012e). Women living with HIV may die from obstetric causes where 
HIV-infection or AIDS is not the underlying cause of death. On the other hand, women might die 
of an HIV- or AIDS-related condition—like pneumocystis pneumonia—that is not related to 
pregnancy and thus should not be coded as a maternal death. Only if pregnancy contributed to an 
HIV-related death should HIV be coded as a cause of maternal death (ICD code O98.7) (WHO 
2012e: 19). Alternatively, if HIV disease contributed to an obstetric complication that caused a 
maternal death (e.g. sepsis) it would be listed as a contributing factor. 
The causal relationships and interactions between HIV disease, pregnancy, disease 
progression and maternal deaths are research questions that remain to be answered. Recording all 
deaths during pregnancy among women with HIV and improving the quality of death certificates 
will contribute to elucidating these relationships. 
However, better death certificates will not solve all problems. Even at tertiary-level 
hospitals, autopsy studies reveal significant misdiagnoses in cause of maternal death. For 
example, a study from Mozambique identified major diagnostic errors (mistaken cause of death 
that resulted in inadequate treatment) in 40% of maternal deaths; for 12 out of 18 women with 
HIV who died the underlying cause of death was misdiagnosed (Ordi, Ismail et al. 2009). There 
is a need to conduct more autopsies, expand maternal death audits, and conduct verbal autopsy 
studies of maternal deaths, particularly where a significant proportion of births take place outside 
of institutions. Advances in minimally-invasive autopsies that could be carried out in the field, 
improvements to verbal autopsy tools, and community-based data collection (in some cases 
facilitated by mobile technologies) are promising avenues for improving the availability and 
quality of data. 
More information is also required about maternal morbidity, which is much more 
common than mortality, and takes a huge toll on the health and well-being of women 
internationally. A recent scoping exercise by the WHO found that the existing literature and 
experts did not share uniform criteria for the identification and classification of maternal 
morbidity, including severity and time frame (Firoz, Chou et al. 2013). The Maternal Morbidity 
Working Group is working to develop and validate an assessment tool for measuring maternal 
morbidity at the community and primary-health-care levels and develop indicators of maternal 



















cases of maternal morbidity using methodologies such as “near misses” which identify women 
who experienced serious complications but survived, or calculating the Case Fatality Rate, will 
generate needed information (Souza, Cecatti et al. 2012). 
Program monitoring and evaluation could play an important role in generating evidence
needed for improving national and international responses to HIV and maternal morbidity and 
mortality. However, routine monitoring and evaluation is weak in many countries. There is a 
paucity of data on actual maternal or neonatal health outcomes in contexts of integrated service 
delivery and very few studies report on the utilization and/or outcomes based on the HIV-status 
of pregnant and postpartum women and their children (Nutman, McKee et al. 2013). 
The tendency of implementation research to only measure process indicators (utilization
and coverage) rather than outcome indicators (health status) or to confine reporting to a single 
short-term health outcome limits our ability to evaluate program effectiveness and impact on 
multiple health outcomes (Lindegren, Kennedy et al. 2012). Implementation science, which 
tracks rare events like maternal mortality over time and takes into account multiple, medium 
term health outcomes (like incident pregnancy, new HIV and other sexually transmitted 
infections, malaria, and tuberculosis), is urgently needed. In general, information about the cost 
of program implementation and cost-effectiveness is lacking.
Finally, while there is increasing recognition that the social determinants of health have 
an important gender component and there are numerous large-scale initiatives to reduce barriers 
to care for pregnant women through conditional cash transfer programs, healthcare coverage 
schemes and financial incentives to attend prenatal and labor and delivery services, less attention 
has been paid to the effects of intrapersonal quality of care, community engagement and social 
support (including participation of male partners) on proximate measures (uptake and retention 
in HIV care, facility delivery, disclosure of HIV-status, postpartum depression, and adherence to 
antiretroviral treatment) and health outcomes (violence against women, maternal morbidity and 
mortality, quality of life). Evaluation of community-based, participatory and rights-based 
interventions and implementation research on programs which aim to create an enabling 
environment for women to begin and remain in MCH and HIV services are priorities.  
In conclusion, better evidence about the relationship between HIV and maternal 







system to improve maternal health outcomes are needed to guide programming and policy. 
Fortunately, in spite of significant problems with data quality, completeness, and availability, 
there are opportunities to conduct secondary analyses, draw on data generated through routine 
monitoring and evaluation, advocate for the inclusion of indicators in routine programming 
monitoring and periodic population-based studies, improve tools (such as verbal autopsies), and  
leverage ongoing research and implementation science to answer key questions. Finally, to 












   
 
 
   
  
Research Priority 1: Clinical Questions about Maternal Mortality
and HIV
Women with HIV in sub-Saharan Africa are six to eight times more likely to die during 
pregnancy and the six week postpartum period than are their HIV-negative counterparts (Calvert 
and Ronsmans 2013a, Zaba, Calvert et al. 2013). Research is needed to determine whether 
pregnancy has an independent effect on mortality among women living with HIV and how risk 
of morbidity and mortality interacts with immune parameters and time on ART. Several studies 
and reviews have found that pregnancy does not seem to accelerate HIV disease progression or 
time to death either before or after the availability of antiretroviral treatment, however high rates 
of loss to follow-up may have contributed to underestimation of mortality (Tai, Udoji et al. 2007, 
MacCarthy, Laher et al. 2009, Westreich, Maskew et al. 2013). A recent prospective cohort study
of women initiating ART in Uganda found no significant differences when comparing crude 
mortality rates between women who had a pregnancy and those who did not, however when 
pregnancy and the one-year postpartum period was treated as a time-dependent risk factor, 
significantly higher pregnancy-related mortality was identified (Matthews, Kaida et al. 2013). 
These findings should be interpreted cautiously as only five deaths of pregnant and postpartum 
women occurred (Matthews, Kaida et al. 2013). 
Questions related to the impact of pregnancy on HIV progression and, conversely, the 
impact of HIV and pregnancy on infections such as TB and malaria, are complicated by the 
“healthy pregnancy effect”. Fertility is reduced as HIV disease progresses, thus women living 
with HIV who become pregnant tend to be healthier than women who do not become pregnant. 
The healthy pregnancy effect complicates comparisons of rates of morbidity and mortality 
between pregnant and non-pregnant women living with HIV, and requires more research which 
controls for immune parameters and treatment status.
How increased availability of ART in low-resource settings will change the causes and 
patterns of maternal and neonatal morbidity and mortality remains to be determined. As 
countries implement the new World Health Organization Guidelines for ART during pregnancy, 
initiate treatment earlier (at CD4+ cell count of 500 cells/uL rather than a CD4+ cell count of 
350 cells/uL), and offer pregnant, breastfeeding and postpartum women lifelong ART 











   
   
   
 
  




          
 
  
will be on ART continuously (WHO 2013a). Understanding the impact of increased use of ART 
at conception, during pregnancy, and postpartum for women and children’s health is a research 
priority. Finally, there are outstanding clinical questions about how to best manage pregnant and 
postpartum women with HIV to reduce morbidity and mortality.
Priority Research Questions




•	 How will rates and causes of morbidity and mortality during pregnancy and the 

postpartum period be affected by increased availability of ART for women of 

reproductive age living with HIV, including provision of Option B+?

•	 Does pregnancy influence the progression of HIV disease?
•	 What research designs are most appropriate for adjusting for the healthy pregnancy effect 
and ensuring valid comparisons between groups of pregnant and postpartum women 
living with HIV as well as those who are not pregnant? 
Key Outcomes and Variables: 
HIV status, pregnancy/postpartum status, currently on ART, gestational age (or trimester) at 
initiation or on ART at conception, time on ART, ART regimen, CD4 and viral load (most recent 
and at treatment initiation), WHO disease stage, cause of death, causes of maternal morbidity, 
type of delivery (vaginal or cesarean), perinatal outcome (live or stillbirth), cost-benefit and cost-
effectiveness.
Cause of Death among Pregnant and Postpartum Women with HIV
The majority of maternal deaths in women with HIV are attributed to non-pregnancy 
related infections. For example, an autopsy study of maternal deaths among women with HIV 
found HIV or AIDS related conditions to be the most common cause of death, followed by 
tuberculosis, bacterial pneumonia, and severe malaria, while the main obstetric causes of death 
were puerperal septicemia and eclampsia (Menendez, Romagosa et al. 2008) . In South Africa, 




















pregnancy related infections (cause specific Institutional Maternal Mortality Ratio iMMR 267.3 
per 100, 000 live births vs. 6.6 among HIV-negative); obstetric hemorrhage (iMMR 38.4 HIV+ 
vs. 17.1 HIV-); hypertension (iMMR 27.4 HIV+ vs. 18.8 HIV-); sepsis (iMMR 24.2 HIV+ vs. 
4.1 HIV-); and medical and surgical disorders (iMMR 24.2 HIV+ vs. 11.5 HIV-) (Sebitloane 
2013). Between 2008 and 2010, two-thirds of South African women with AIDS who died during 
pregnancy or six weeks postpartum had respiratory complications, namely TB (26.9%), 
pneumocystis pneumonia (13.3%) and other non-specified pneumonia (26.7%); the second most 
common contributing cause of death in women with AIDS was meningitis (12.9%) (Moodley 
and Pattison 2012). In Nigeria, between 2005 and 2009, 62% of maternal deaths among women 
with HIV were from indirect causes, specifically cerebral infections, tuberculosis, pneumonia 
and AIDS (Danel 2013). The expert meeting convened by the CDC, USAID and the MHTF in 
June 2013 prioritized the following contributors to and causes of maternal death for future 
research: sepsis, obstetric hemorrhage, hypertension, anemia, malaria, pneumonia, and 
tuberculosis. 
Research Questions
•	 What is the impact of ART on maternal morbidity and mortality caused by or associated 
with: sepsis, obstetric hemorrhage, hypertension, anemia, malaria, pneumonia, and 
tuberculosis?
•	 How are maternal morbidity and mortality related to: women’s immune status (CD4 and 
viral load); time on treatment and timing of treatment initiation in relation to conception 
and gestation; treatment regimen?
Sepsis
Women living with HIV are more likely to experience puerperal sepsis than their HIV-
negative counterparts, particularly if they are immunocompromised (CD4+ cell count under 200 
cells/uL), and are more likely to die as a consequence. For instance, in South Africa, in the 
period between 2008 and 2010, the iMMR from puerperal sepsis was six times higher among 
women with HIV than HIV-negative women (24.2 per 100,000 live births vs. 4.1 per 100,000 
live births) (Chweneyagae, Delis-Jarrosay et al. 2012). A US study comparing pregnancy 












   
   
   
 
 
included women who had both vaginal and cesarean deliveries found that women with HIV were 
more than twice as likely to experience puerperal sepsis (AOR 2.27) (Bansil, Jamieson et al. 
2007). A US study which compared women living with HIV and HIV-negative women who had 
a cesarean section between 1999 and 2002 found women living with HIV to have 6 times the 
rates of puerperal sepsis (AOR 6.2) (Louis, Landon et al. 2007). A recent systematic review of 
obstetric complications and HIV-status reinforced findings that women with HIV are more likely 
to experience puerperal sepsis and that cesarean delivery greatly increases women’s risk. Meta-
analysis found that women living with HIV were more likely to experience puerperal sepsis (OR 
3.43) and that when women delivered by cesarean section the risk of puerperal sepsis was almost 
six times greater than among HIV-negative women (OR 5.81) (Calvert and Ronsmans 2013a, 
see also Bjorklund, Mutyaba et al. 2005, van den Akker, de Vroome et al. 2011). It is also known 
that in South Africa, women with HIV bear a disproportionate burden of maternal deaths due to 
abortion—from 2005 to 2007, for deaths for which women’s HIV status was known, 89% of 
deaths related to abortion were among women with HIV (Moran and Moodley 2012).
Compromised immune status is also associated with a higher rate of sepsis among 
women with HIV who give birth vaginally. In a South African study women with a CD4+ cell 
count of <200 cells/uL had much higher rates of infectious morbidity than HIV-negative women 
while women with CD4+ cell count above 200 cells/uL were no more likely than HIV-negative 
women to experience infectious morbidity (incident rate ratio 0.69) (Sebitloane, Moodley et al. 
2009). Factors which significantly increased puerperal infections among women with HIV and 
HIV-negative women were episiotomy (p<0.001), the number of vaginal examinations after 
rupture of membranes (p<0.026), and CD4+ cell counts below 200 cells/uL among women living 
with HIV (Sebitloane, Moodley et al. 2009). Results of the impact of providing prophylactic 
antibiotics to women with HIV prior or during delivery have been mixed, with one South African 
Randomized Controlled Trial (RCT) finding a significant reduction in sepsis and endometriosis 
with antibiotics compared to placebo, and a multisite RCT in Malawi, Tanzania and Zambia 
finding no difference in puerperal sepsis between pregnant women with HIV given prophylactic 
antibiotics when compared to placebo (Sebitloane, Moodley et al. 2008, Aboud, Msamanga et al. 





















                                                
            
delivery and as part of postpartum and post-abortion care, as well as on the relationship between 
sepsis, immune status, and ART. 
Research Questions
•	 Will earlier initiation of ART eradicate differences in maternal morbidity and mortality 
related to sepsis between women with HIV and HIV-negative women?
•	 Are different prophylaxis and clinical management of sepsis indicated for women living 
with HIV during post-abortion and labor and delivery care (particularly caesarean 
section)?
•	 What are the relative outcomes of giving antibiotics prophylactically or therapeutically 
on rates of sepsis?
Obstetric Hemorrhage
Obstetric hemorrhage may not be more common among women living with HIV than 
HIV-negative women, but it may have more serious consequences. A meta-analysis found that 
women living with HIV had double the odds of antepartum hemorrhage (OR 2.06) compared to  
HIV-negative women but no evidence that HIV increases the odds of postpartum hemorrhage 
(Calvert and Ronsmans 2013a). A study conducted between April and August 2012 in four South 
African hospitals found that overall obstetric hemorrhage rates were 2.5% and there was no 
significant difference between women living with HIV (2.68%) and HIV-negative (2.35%) 
women. Nevertheless, the incidence of anemia at admission (p <0.0001) and blood transfusion 
among women living with HIV (OR 1.53) were both significantly higher than among HIV-
negative women, though units of blood transfused did not differ between women with HIV and 
other women (Bloch, Crookes et al. 2013).5 The South African Maternal Death Review estimated 
that the iMMR for obstetric hemorrhage was 38.4 for women living with HIV as opposed to 17.1 
for HIV-negative women in the period between 2008 and 2010 (Sebitloane 2013). The effect of 
antiretroviral treatment on blood vessels, the myometrium, and possible contribution to obstetric 

























hemorrhage is unknown. The question of whether women with HIV experience treatment delays 
or substandard care because of HIV-related stigma and providers’ fear of HIV transmission 
remains to be answered.  
Research Questions
•	 Is hemorrhage more severe among women with HIV than HIV-negative women after 
controlling for the presence of anemia?
•	 Does ART increase or mitigate the incidence of morbidity and mortality associated with 
maternal hemorrhage?
•	 Do women living with HIV experience longer delays in receiving care for obstetric 
hemorrhage than other women?
•	 Are interventions to prevent and manage hemorrhage as effective among women living 
with HIV as among other women?
Anemia
Pregnancy, HIV infection, HIV treatment, and other infections such as tuberculosis and 
malaria can all contribute to women developing anemia. The causes of anemia in women with
HIV include anemia of chronic disease, immune mediated red cell destruction, bone marrow 
infections, neoplasms, malnutrition and malabsorption related to HIV infection, as well as 
adverse effects of antiretroviral treatment, particularly zidovudine (ZDV). Several studies from 
sub-Saharan Africa have reported very high rates of anemia among pregnant women living with 
HIV who were not taking antiretroviral treatment: 78% in Burkina Faso (Meda, Dao et al. 1998), 
82% in Tanzania (Villamor, Dreyfuss et al. 2004) , 83% in Cote d’Ivoire (Ramon, Sawadogo et 
al. 1999), and 73% in an analysis of a multicenter trial conducted in Tanzania, Zambia and 
Malawi (Mehta, Manji et al. 2008). In a longitudinal Tanzanian study of pregnant women with 
HIV where 87% of women developed incident anemia over the two year period postpartum, 
infections with malaria and pathogenic protozoa were associated with a two-fold increase in the 
risk of developing anemia, as were lower CD4 counts (Finkelstein, Mehta et al. 2012). 
In the context of HIV, anemia has been shown to have negative impacts on maternal and 
child health. Anemia has been associated with disease progression among women living with 












           









   
before availability of ART showed that HIV and anemia were both associated with maternal and 
non-maternal deaths, though the association with maternal deaths was no longer statistically 
significant in multivariate analysis (McDermott, Slutsker et al. 1996).  A multicenter PMTCT 
study (using SD-NVP) in Tanzania, Zambia and Malawi associated  severe anemia with 
stillbirth, preterm birth, low birth weight, and mother-to-child transmission of HIV at birth and in 
the six week postpartum period (Mehta, Manji et al. 2008). A recent Nigerian study from an 
urban hospital where women had access to ART associated anemia in pregnant women living 
with HIV with shorter time between pregnancies, presence of other opportunistic infections, 
lower CD4 count, and taking a ZDV containing regimen (Ezechi, Kalejaiye et al. 2013). Despite 
the association between ZDV and anemia, the study also found that beginning ART before 
pregnancy was protective against anemia (Ezechi, Kalejaiye et al. 2013).
Controversies about Iron Supplementation during Pregnancy in Women Infected with or
who have a High Risk of Acquiring HIV, Tuberculosis, or Malaria
There is some controversy about how to address anemia in pregnant women who are 
infected with or have a high risk of acquiring HIV, tuberculosis or malaria. Iron supplementation 
is the only specific treatment for iron deficiency but in the presence of chronic infections such as 
malaria, HIV and tuberculosis there is concern that excess iron may increase the replication of 
infectious agents. In a study of postpartum women living with HIV in Zimbabwe, elevated iron 
stores were associated with higher viral load and HIV-related maternal mortality during the 
subsequent year; this effect was only found among non-anemic women which led the authors to 
posit that iron is being prioritized for red blood cell production in anemic women and is thus not 
available for viral replication (Rawat, Humphrey et al. 2009). Results from studies of antenatal 
iron supplementation on malaria outcomes are contradictory, with some studies finding increased 
prevalence of malaria in pregnant women after supplementation and others not finding this 
association (Oppenheimer, Macfarlane et al. 1986, Menendez, Todd et al. 1994, Nacher, 
McGready et al. 2003, Haider, Olofin et al. 2013). There is a lack of evidence about how best to 
treat anemia among people living with HIV (Marti-Carvajal, Sola et al. 2011). WHO does not 


















                                                
             
   
 
on HIV-status6 but notes that more research is needed on the use of iron supplementation in 
pregnant women living with HIV (WHO 2003:8-9).
Research Questions
•	 Will rates of anemia continue to be elevated among pregnant women living with HIV if 
ART is begun earlier and ZDV-containing regimens are used less frequently?
•	 Will timely diagnosis and treatment of malaria and tuberculosis reduce prevalence and 
severity of anemia among pregnant and postpartum women living with HIV?
•	 Is routine iron supplementation without verifying the presence of anemia warranted for 
pregnant women in areas where there is a high prevalence of both malaria and HIV?
•	 Does ART modify any effects of iron supplementations on HIV and malarial replication, 
obviating concerns about its use?
Malaria7 
Approximately one million pregnancies are complicated by both malaria and HIV 
infection in sub-Saharan Africa annually (Brentlinger, Behrens et al. 2006). Both infections have 
been associated with maternal, as well as infant, morbidity and mortality (Brentlinger, Behrens et 
al. 2006).  Pregnant women with HIV are at increased risk of malaria because of HIV and 
pregnancy-related depression of immune response, and have a higher incidence and density of 
malaria parasites than uninfected pregnant women (ter Kuile, Parise et al. 2004, Alban and 
Andersen 2007, Briand, Badaut et al. 2009, De Beaudrap, Turyakira et al. 2013). Pregnant 
women with HIV who are co-infected with malaria experience greater rates of febrile illnesses 
and adverse birth outcomes such as low birth weight, prematurity, and intrauterine growth 
restriction (ter Kuile, Parise et al. 2004).  Co-infection with HIV and malaria is also associated 
with developing anemia and increased risk of severe anemia during pregnancy (Ayisi, van Eijk et 
6 400 mg of folate and 60 mg of iron daily to prevent anemia and double that dose to treat severe anemia (WHO
2003: 8).
7  Malaria prevention is discussed in Research Priority 2: Integrating Health Service Delivery to Address Maternal 












    
  
 
                                                
                
               
               
 
al. 2003, Finkelstein, Mehta et al. 2012). Women with HIV who also have malaria are at 
increased risk of maternal death (OR 5.05, CI 2.12-12.04) (Ticconi, Mapfumo et al. 2003).
Antimalarial treatment on the basis of clinical suspicion of malaria (without parasitological 
confirmation if unavailable) is recommended for pregnant women in stable high-transmission 
settings where there is a high prevalence of HIV (WHO 2010a: 12).
Treating HIV and malaria co-infection in pregnant women presents several challenges. 
There are known drug interactions between antiretrovirals, cotrimoxazole used for prophylaxis in 
immunocompromised women with HIV (which is also preventive treatment for malaria), and 
other antimalarial drugs. There is limited information at present on how HIV infection modifies 
the therapeutic responses to the preferred and more effective arteminisin-based combination 
therapy (ACTs) or on interactions between antimalarial medicines and antiretrovirals for the 
general population living with HIV (WHO 2010a: 32). In their review of adverse effects of 
antiretroviral and antimalarials commonly used during pregnancy in developing countries, 
Bretlinger and colleagues recommend cautious use of sulfadoxine-pyrimethamine (SP) (a less 
effective antimalarial agent) in women who are concurrently receiving daily NVP and/or ZDV 
and avoiding SP if women are taking daily cotrimoxazole because of increased toxicity and 
adverse effects and because cotrimoxazole provides prophylaxis for malaria (Brentlinger, 
Behrens et al. 2006). In fact, one study found cotrimoxazole to be more effective than 
Intermittent Preventive Treatment of Malaria in Pregnancy (IPTp) with SP among pregnant 
women with HIV (Kapito-Tembo, Meshnick et al. 2011). This raises the question of whether 
women living with HIV in malaria endemic areas should remain on cotrimoxazole after their 
CD4+ cell count goes above 350 cells/uL (Kamya, Byakika-Kibwika et al. 2012). 8 There are no 
reported drug interactions between SP and the fixed-dosed once a day combination that is being 
recommended by the World Health Organization for pregnant women and women of 
reproductive age (Atripla: Efavirenz, Emtricitabine, Tenofovir) (WHO 2013a). Co-
administration of antiretroviral and antimalarial drugs creates the potential for pharmacokinetic 
8 In settings with a high prevalence of bacterial infections or malaria the 2013 WHO Antiretroviral Treatment
Guidelines recommend ongoing treatment with cotrimoxazole or waiting until CD4+ cell count is above 350



















drug interactions that may increase (causing enhancement of malaria treatment efficacy and post-
treatment prophylaxis and/or unanticipated toxicity) or reduce drug exposure (creating risk for 
treatment failure). Further studies are needed to elucidate the clinical implications of potentially 
important pharmacokinetic interactions between commonly used antimalarials, ARV, and 
cotrimoxazole (Kamya, Byakika-Kibwika et al. 2012).
The pregnancy specific immunity to malaria seen in HIV-negative women is diminished 
in women living with HIV and response to IPTp is impaired (Flateau, Le Loup et al. 2011). More 
doses of SP may improve outcomes among pregnant women with HIV and their infants, as well 
as among pregnant women in general (WHO 2013b). Two randomized trials (one in Malawi and 
one in Zambia) comparing monthly SP to the standard 2-dose regimen found that for pregnant 
women living with HIV, monthly SP reduced maternal and placental parasitaemia at delivery,  
maternal anemia, and the number of low birth weight babies (Mathanga, Uthman et al. 2011).
New WHO guidelines on ITPp with SP recommends giving a directly observed dose of SP to 
every pregnant woman at each scheduled ANC visit, provided that the doses are given at least 
one month apart; SP should not be given during the first trimester but can be administered up to 
the time of delivery without safety concerns (WHO 2013b). 
Women in second and third trimesters of pregnancy are more likely to develop severe 
malaria than other adults, and in this scenario, maternal mortality is approximately 50% (WHO 
2010a: 47). To treat severe malaria during the second and third trimester of pregnancy, WHO 
recommends parenteral artesunate over quinine because about 50% of women with severe 
malaria treated with quinine late in pregnancy experience hypoglycemia (WHO 2010a: 47, 91).
However, there is also the recommendation that people with HIV who are receiving ZDV or 
EFV should, if possible, avoid amodiaquine containing artemisinin-based combinations because 
of risk of neutropaenia with ZDV and hepatoxicity with EFV; recommendations for treating 
pregnant women with severe malaria on ART are not specified (WHO 2013a: 167). 
Research Questions
•	 What combinations of prophylactic agents like cotrimoxazole, ARV and drugs to prevent 

























•	 What is the optimal clinical protocol for treating pregnant women with HIV who also 
have severe malaria, including in the context of labor and delivery?
•	 What are the effects of first trimester exposure to artemisinin on neonatal health?
Pneumonia
Pneumonia is a leading cause of maternal death among women with HIV in sub-Saharan 
Africa (Moodley and Pattison 2012, Sebitloane 2013). Between 2008 and 2010 in South Africa, 
13% of maternal deaths among women with AIDS were caused by pneumocystis pneumonia and 
27% by non-specified pneumonia (Moodley and Pattison, 2012). A US review of 22 cases of 
pneumocystis pneumonia in pregnant women living with HIV who had a mean CD4+ cell count
of 98 cells/uL when ART was not available found that half of the women died—a much higher 
mortality rate than reported for people with HIV due to pneumocystis pneumonia at that time 
(Ahmad, Mehta et al. 2001). Even in high-income, well-resourced settings, late diagnosis with 
HIV and pneumonia during pregnancy can be fatal (Parisaie, Hemelaar et al. 2010). The burden 
of pneumonia deaths among pregnant women with HIV highlights the importance of HIV-testing 
in early pregnancy, prompt access to ART, and cotrimoxazole prophylaxis for those with CD4+ 
cell counts below 350 cells/uL.
Research Questions 
•	 What are the specific microbial causes of pneumonia mortality in pregnant women with 
HIV?
•	 After how much time on ART and at what CD4 counts does the incidence of pneumonia 
among pregnant women living with HIV approximate the baseline rates of pregnant 
women who do not have HIV?
•	 What are the optimal clinical protocols for identifying and treating pneumonia among 


















     
 
 
                                                
            
     
 
Tuberculosis9 
The risk of developing TB is between 21 and 34 times greater in people living with HIV 
than among HIV-negative individuals (Sculier and Getahun 2011). TB remains the leading cause 
of death among people with HIV in sub-Saharan Africa; a review of autopsy studies done 
between 1993 and 2010 in 12 African countries identified TB as the cause of death in 32-45% of 
cases (Cox, Lukande et al. 2010). Women living with HIV who have TB disease have a two to 
threefold higher risk of maternal mortality two to three fold as compared to pregnant women 
with TB disease who are HIV-negative (Khan, Pillay et al. 2001, Gupta, Nayak et al. 2007). 
Immune suppression during pregnancy may mask symptoms of TB while increasing 
susceptibility to the development of TB disease. A large study recently found that during the first 
six months postpartum, women were twice as likely to develop TB disease as women who had 
not had a pregnancy (Zenner, Kruijshaar et al. 2012). HIV infection further increases the 
probability of developing TB disease. A South African study found that pregnant women living 
with HIV had a tenfold higher risk of developing active TB than HIV-negative pregnant women
(Pillay, Khan et al. 2001). Rates of active TB disease range from 0.7% to 7.9% among women 
living with HIV in high-burden countries (Mathad and Gupta 2012). Latent TB is highly 
dependent on the underlying population prevalence. One indicator of the importance of screening 
for and providing prophylaxis to pregnant women in countries with high burden of HIV are 
reports of latent TB prevalence as high as 49% among women living with HIV in South Africa 
(Nachega, Coetzee et al. 2003). TB infection of the placenta can increase HIV placental viral 
load and increase mother-to-child transmission (Ezechi, Odberg Petterson et al. 2012). 
Despite the devastating interactions between HIV, TB and pregnancy, optimism can be 
drawn from a recent meta-analysis which found that ART reduces opportunistic infections in low 
and middle-income countries, including both pulmonary and extra-pulmonary TB (Low, 
Gavriilidis et al. 2013). ART reduced the risk of TB by up to 65%, even in people with high CD4 
cell counts suggesting that earlier initiation of ART may be a key strategy for reducing HIV-
9 Screening and prophylactic treatment are addressed in Research Priority 2: Integrating Health Service Delivery to 























associated TB (Suthar, Lawn et al. 2012). Isoniazid Preventive Therapy (IPT) for 6 months and 
early initiation of ART are the mainstays of tuberculosis prevention among pregnant women 
living with HIV. Isoniazid is not teratogenic even when used in the first trimester which implies 
that it can be given at any stage of pregnancy (Getahun, Granich et al. 2010). WHO recommends 
initiation of IPT in people with HIV who are unlikely to have active TB, even in the absence of a 
tuberculin skin test because IPT does not increase risk of developing isoniazid resistant TB; past 
history of TB and current pregnancy are not contraindications for initiating IPT (WHO 2013a: 
160-161). A recent randomized placebo-controlled study from Botswana which examined a sub-
sample of women living with HIV who became pregnant while taking IPT provided reassuring 
findings for both maternal and infant health. None of the 103 women exposed to isoniazid during 
pregnancy or the immediate postpartum period experienced severe hepatitis or rash and isoniazid 
exposure was not associated with adverse outcomes among infants (Taylor, Mosimaneotsile et al. 
2013). Studies conducted in Brazil and South Africa have shown up to 90% reduction in the risk 
of contracting TB among people living with HIV who received both ART and IPT. Whether 
pregnant women experience a similar additive benefit from ART and IPT remains to be assessed 
(Getahun, Granich et al. 2010). 
The World Health Organization recommends a six month rifampicin containing regimen 
to treat TB disease in people living with HIV (WHO 2013a). While rifampicin is contraindicated 
with nevaripine and protease inhibitors, it is compatible with the EFV containing once daily 
regimen that is recommended as first-line treatment for all adults, including pregnant women 
(WHO 2013a). Data assessing the safety, tolerability, and long-term treatment outcomes of 
pregnant women living with HIV and postpartum women on ART with TB disease are scarce
(Mathad and Gupta 2012). One of the very few studies to report on clinical outcomes of 
concurrent TB treatment with rifampicin and ART among 33 pregnant women living with HIV
from the MTCT-Plus cohort found one death and elevated rates of pregnancy loss among women 
who were treated for TB compared with pregnant women who took ART alone (15.2% vs. 5.9%) 
(Toro, Schneider et al. 2011). However, in this study, there was significant heterogeneity in the 
ART regimens taken by women with 33% receiving a nevaripine-containing regimen (which 
was contraindicated) and 33% receiving the abacavir-containing regimen which was 





















   
 
 
al. 2011). Existing studies suggest that EFV-based ART is safe with rifampicin, with no 
significant differences in EFV levels, HIV virologic suppression, or six-week mother-to-child 
HIV transmission rates as compared to HIV-positive women without TB (McIlleron, Martinson 
et al. 2012). 
The following medications for treating tuberculosis are contraindicated in pregnant 
women: streptomycin, kanamycin, amikacin, capreomycin and fluroquinolones (CDC 2011, 
WHO 2010c). Pregnant women who are being treated for drug resistant TB disease should be 
counseled concerning risks to the fetus because of known and unknown risks of second-line 
tuberculosis medications (CDC 2011). Despite these concerns, treatment of TB disease among 
pregnant women living with HIV is crucial and women should be treated for both HIV and TB 
(Mathad and Gupta 2012). 
Studies funded by the National Institutes of Health (NIH) are underway to assess optimal 
timing of isoniazid for women living with HIV (IMPAACT P1078), pharmacology of TB
treatment in pregnant and postpartum women (both those who are HIV-negative and living with 
HIV) (IMPAACT P1026s), and outcomes of pregnant women with TB (RO1HD06435). A TB
pregnancy register, similar to the ART Pregnancy Registry or the WHO Pregnancy Registry 
Database should be developed to collect safety and outcome data from pregnant women taking 
treatment for TB. There is a need for research which includes pregnant and postpartum women 
living with HIV who are on ART to determine the safety and optimal timing for active and 
multidrug resistant TB treatment (Mathad and Gupta 2012). 
Research Questions
•	 What is the impact of early ART initiation on the prevalence of tuberculosis among 
pregnant women with HIV?
•	 Does early initiation of ART and provision of IPT to pregnant women with HIV offer the 
same additive protective effect against development of TB as has been observed in other
populations of people living with HIV (PLHIV)?
•	 What treatment regimens for active TB and multi-drug resistant TB are safe and effective 
















Hypertensive disorders during pregnancy are an important cause of maternal death 
internationally and are the cause of an estimated 9% of maternal deaths in Africa (Khan, 
Wojdyla et al. 2006). The role of ART in the pathogenesis of hypertension is not well 
understood, however ART is linked to a series of metabolic abnormalities associated with 
hypertension, including insulin resistance, diabetes, and elevated cholesterol and triglyceride 
levels (Falutz 2007). As ART is introduced in low-income settings and HIV becomes a chronic 
rather than acute condition, greater frequency of metabolic complications can be expected. 
Single hospital studies from South Africa and from Ethiopia found hypertension rates of 19% 
and 35%, respectively, among patients who had been on ART for at least one year (Julius, Basu 
et al. 2011). An observational US study which compared women living with HIV to HIV-
negative women found pregnancy to be protective against hypertension (p<0.04). In this cohort,
hypertension was associated with being African American, older, and overweight; these 
associations did not vary by HIV status. For women living with HIV, hypertension was not 
associated with differences in CD4 count, viral load or antiretroviral regimen (Khalsa, Karim et 
al. 2007). In contrast, a study conducted in Botswana found that pregnant women living with 
HIV on ART were significantly more likely to have placental pathology consistent with chronic 
hypertension than their peers who were not taking ART (65% vs. 28% p=0.003) (Shapiro, Souda 
et al. 2012). The birth outcomes from this study independently associated maternal hypertension 
with increased risk for pre-term delivery, babies small for gestational age, and stillbirth (Chen, 
Ribaudo et al. 2012). 
Pre-eclampsia and eclampsia are major causes of maternal morbidity and mortality 
(WHO 2011b). Pre-eclampsia research with women living with HIV has been limited. Some 
studies from both high and low-income settings suggest that pregnant women living with HIV 
who are not taking ART are less likely to develop pre-eclampsia than HIV-negative pregnant 
women (Kalumba, Moodley et al. 2013, Suy, Martinez et al. 2006). Studies in high-income 
settings have reported conflicting findings about the relationship between ART and pre-
eclampsia, with some studies reporting an increase in pre-eclampsia with ART and others 
showing no difference in rates of pre-eclampsia between pregnant women living with HIV on 






















Mma Bana study in Botswana, only having a high viral load was significantly associated with 
pre-eclampsia, though there was a trend towards developing pre-eclampsia with a CD4+ count of 
less than 200 cells/uL and depending on the type of ART regimen (Powis, McElrath et al. 2013). 
The rate of stillbirths among pre-eclamptic women living with HIV was 64% as opposed to 2% 
in the total cohort (Powis, McElrath et al. 2013) . As ART is scaled-up in low and middle-
income countries, larger studies and more research are needed to clarify the relationships 
between ART, immune status, the hypertensive disorders of pregnancy with a focus on pre-
eclampsia and eclampsia, and maternal and infant outcomes. 
Research Questions
•	 What are the interactions between ART, pregnancy and hypertension?
•	 Will provision of ART result in increased rates of pre-eclampsia and eclampsia among 
women with HIV?
•	 What are the associations between ART, hypertension and adverse infant outcomes such 
as pre-term delivery, infants that are small for gestational age, and stillbirth?
Impact of Antiretroviral Treatment on Maternal and Neonatal Health
Several prospective and retrospective studies from sub-Saharan Africa which assessed
ART during pregnancy and in the postpartum period have found lower mortality in the group of 
women with HIV who received ART as compared to those who did not receive ART, suggesting 
both that there is maternal benefit to extended use of ART postpartum and that being on ART for 
a longer period during pregnancy has benefit for maternal survival (Kuhn, Semrau et al. 2009 , 
Marazzi, Palombi et al. 2011, Jamieson, Chasela et al. 2012). A prospective analysis of deaths 
during pregnancy and one-year postpartum among women initiating ART in Uganda found that 
the pregnancy-associated risk of mortality was greatest in the first year of ART with a steady 
decline over time and that by the second year on treatment women who became pregnant had no 
greater risk of death (Matthews, Kaida et al. 2013).  However, caution should be exercised in 





















reductions in maternal mortality associated with ART, and in some cases the findings are based 
on small numbers of participants.   
A recent systematic review from the London School of Hygiene and Tropical Medicine 
found no reduction in the risk of mortality during pregnancy and up to one year postpartum 
period when women took ART, but the available studies were undertaken when treatment 
availability was scarce and the treatment guidelines of most countries recommended beginning 
treatment at CD4+ cell count of 200 cells/uL (Calvert and Ronsmans 2013b). Another analysis 
using data from the Analysing Longitudinal Population-based HIV/AIDS data on Africa 
(ALPHA) network of demographic surveillance sites in eastern and southern Africa found a 
large drop in the mortality ratio post-ART as compared with pre-ART among women who were 
not pregnant or postpartum (RR 0.42 p<0.0001), and a smaller reduction among women who 
were pregnant and up to six weeks postpartum (RR 0.70, p=0.205). Again, the small reduction in 
the maternal mortality ratio (MMR) is probably due in part to the relationship between being in 
good health and becoming pregnant (“healthy pregnancy effect”) and in part to the fact that 
throughout most of the period under study, ART was not widely available and the treatment 
regimen given to prevent mother-to-child HIV transmission was single-dose Nevirapine (Sd-
NVP) which does not confer health benefits to the mother (Zaba, Calvert et al. 2013).
Preliminary data from South Africa indicate a 13% drop in the MMR among women 
with HIV when the Ministry of Health switched from Sd-NVP to NVP-based ART for PMTCT 
and increased the threshold for initiating ART from CD4+ cell count of 200 cells/uL  to a CD4+ 
cell count of 350 cells/uL (Sebitloane 2013, Chweneyagae, Delis-Jarrosay et al. 2012). Even if 
triple therapy is not provided beyond breastfeeding, the provision of ART during the antenatal 
period and breastfeeding is likely to improve women’s health. In Mozambique, Marrazi and 
colleagues showed a clear “dose effect” between a longer period of exposure to antenatal ART 
and reductions in maternal mortality; MMR was 10-fold higher in women with no treatment 
before delivery compared to women with 90 days or more of ART prior to birth (Marazzi, 
Palombi et al. 2011). Immune system preservation and reconstitution through earlier and 
sustained access to ART can be expected to reduce maternal morbidity and mortality among 
women living with HIV. Thus, early initiation of ART (at between a CD4+ cell count of 350 














      
  
 
                                                
                  
              
increasing number of women continuing on lifelong ART after pregnancy, as per new 
international guidelines (WHO 2013a), should lead to declines in morbidity and mortality during 
pregnancy and in the extended postpartum period. 
Notwithstanding, data from South Africa show higher mortality rates among pregnant 
women living with HIV compared to HIV-negative pregnant women even when they are 
receiving ART (Moodley and Pattinson 2012)10. However, late presentation and delayed 
initiation of treatment could be the underlying cause for the persistently elevated rate of deaths 
among pregnant and postpartum women living with HIV in the context of antiretroviral 
availability. More studies are needed to tease out the relationships between pregnancy, time on 
ART, immune status, and maternal morbidity and mortality. Cohort studies which allow valid 
comparisons by controlling for the health status of different groups of pregnant and postpartum 
women living with HIV, and that permit comparisons between women living with HIV and HIV-
negative women can make a significant contribution to the evidence base.
Finally, ART is not without health risks for women and infants. In the 2008-2010 South 
African Maternal Death Confidential enquiries, over a three-year period, 73 women died of side-
effects of ART, increasing from 6.5% of the cause of death of women taking ART in 2008 to 
11.6% in 2010. Most of the deaths were due to liver toxicity and Steven-Johnson syndrome 
associated with the NVP-based ART regimen and coincided with starting pregnant women on 
ART at a CD4+ cell count of 350 cells/uL rather than a CD4+ cell count of 200 cells/uL
(Chweneyagae, Delis-Jarrosay et al. 2012).
Similarly, while ART during pregnancy has impressive health benefits for the infant— 
dramatically reducing the risk of HIV transmission during gestation, labor and delivery, and 
breastfeeding from about 45% to 5% (De Cock, Fowler et al. 2000, Volmink, Siegfried et al. 
2007)—ART has also been associated with higher rates of pre-term delivery and low birth 
weight among infants (Coutsoudis 2013, Newell and Bunders 2013). One large observational 
study from Botswana found that preterm delivery, low birth weight, and stillbirth increased 
among women living with HIV who were taking ART from before conception relative to women 
10 The report covers the period from 2008-2010; before December 2009, ART was initiated at a CD4+ cell count of












   
taking ART only during pregnancy and women who were not on ART (Chen, Ribaudo et al. 
2012). 
Monitoring neonatal outcomes in the context of more widespread ART use is important 
to improve the evidence base about possible relationships between in utero exposure to ARVs 
and other drugs used to treat and prevent opportunistic infections in people living with HIV and 
adverse birth outcomes such as birth defects, stillbirth, low birth weight, and prematurity. Early 
gestational exposure, the developmentally sensitive period when major organ systems are formed 
is of special concern, and can be adequately assessed only when large numbers of women are on 
ART around the time of conception. With many sub-Saharan African and other countries scaling 
up ART for pregnant and breastfeeding women and providing lifelong ART (Option B+), the 
number of children conceived while their mothers are taking ART will increase substantially, 
especially where fertility is high. 
Based on analysis of the existing evidence on efficacy and toxicity as well as the need to 
simplify drug procurement and service delivery in the context of ART scale-up and to promote 
individual adherence, the World Health Organization recommends a once daily fixed dose 
combination for all people living with HIV beginning ART, regardless of pregnancy or 
breastfeeding status (WHO 2012d, WHO 2013a). This 3-drug regimen contains Efavirenz, 
Lamivudine or Emtricitibine and Tenofovir.   While case reports and some small prospective 
observational studies have raised concerns about EFV, international meta-analyses have found 
that there are no significant associations between first trimester EFV use and elevated rates of 
birth defects as compared to the general population (Ford, Mofenson et al. 2010, Ford Calmy et 
al. 2011; Knapp, Brogly et al. 2012). Concerns about the effects of Tenofovir on fetal bone 
development based on animal studies require further monitoring (WHO 2013a).
Ongoing monitoring is needed to clarify relationships between ART exposure and 
adverse as well as beneficial neonatal and maternal health outcomes. The World Health 
Organization, the United States National Institutes of Health, the United States Centers for 
Disease Control and Prevention, and the US Department of State, Office of the Global AIDS 
Coordinator through the President’s Emergency Plan for AIDS Relief are supporting efforts to 
establish ARV pregnancy registries and to implement birth defects surveillance in sentinel sites 
















   
  
understanding of the impact of ART on maternal and child health can guide clinical practice and 
prepare health systems to mitigate any adverse effects of treatment scale up. 
Research Questions
•	 What is the impact of ART on maternal morbidity and mortality in different country 
contexts? Some of the specific contextual variables to be explored include: ART regimen 
offered to women of reproductive age; initiation and duration of treatment (CD4 count, 
lifelong treatment post-pregnancy or based on immune status, prevalence of co-infections 
such as malaria and tuberculosis).
•	 Does the distribution and rate of maternal death among women with HIV change with 
large-scale introduction of ART?
•	 How do treatment regimen, timing of initiation of treatment, and time on ART affect
maternal morbidity and mortality?
•	 Are ART-related adverse events more common or severe during pregnancy? Is the 
experience of side effects associated with reduced ART adherence among pregnant 
women?
•	 How does ART from before conception and throughout gestation impact on stillbirth, 




        
















Research Priority 1: Moving the Research and Evaluation Agenda Forward
There are opportunities to conduct secondary analysis and improve data collection to 
answer questions about the causes, rates, and distribution of maternal deaths and morbidity in the 
era of ART scale-up, as well as a need to conduct new research.
Secondary Analysis
•	 Conduct secondary analysis using data from Observational Treatment Cohorts 
(prospective and retrospective) and household and community surveys that have collected 
HIV status and other information related to HIV. The population-based survey conducted 
by and housed at the Africa Centre in South Africa, the body of data being generated by 
the ALPHA network, and the TASO cohort in Uganda are only a few of the existing data 
repositories which are being used to conduct relevant research.
o	 The ALPHA Network brings together data from ten community-based 
longitudinal HIV studies in sub-Saharan Africa. All of the sites are phasing in 
information about ART (ever prescribed, ever on or off ART, when started or 
stopped) in verbal autopsy studies. Additionally, seven of the sites can link clinic 
data generated by the studies’ own clinics or by using unique identifiers or other 
variations to match records. Zaba et al. estimated that a quarter of deaths among 
women during pregnancy and up to six weeks in sub-Saharan Africa are 
attributable to HIV.  This estimate was drawn from data generated through the 
ALPHA Network (Zaba, Calvert, et al. 2013). 
o	 The Africa Center Demographic Information System (ACDIS), housed at the 
Africa Centre for Health and Population Studies at the University of Kwazulu-
Natal, collects longitudinal demographic data (e.g. mortality, fertility, migration) 
and since 2003 has conducted HIV testing. An example of the high quality 
research it is possible to conduct using population-based household surveys that 
collect HIV-status is the Tanser et al. (2013) publication which demonstrated that 
an individual in a South African community with high ART coverage (30-40% of 
all infected individuals on ART) was 38% less likely to acquire HIV than 
someone living in a community where ART coverage was below 10%. A similar 
study estimating rates of maternal mortality and cause of death in communities 
with differential rates of ART coverage would make a significant contribution to 
the literature. 
•	 Other key opportunities for conducting secondary analysis to generate better information 
on maternal morbidity and mortality in the context of HIV are country level maternal and 
pediatric death reviews where HIV status is available. Different countries offer 


































epidemiology, programmatic context (for example ART coverage and type of regimen), 
and existing data collection and management systems. 
Improving the Evidence Base and Synergistic Knowledge Generation with Ongoing
Research or Programs
•	 Advocate for the inclusion of indicators that will permit analysis of the relationship 
between HIV and maternal health (HIV status, pregnancy/postpartum status, on or off 
ART, time on ART, measures of immune status such as CD4 and viral load ) in national 
and international routine and periodic monitoring
o	 Nationally, data collection opportunities include Maternal Death Reviews, 
program monitoring of HIV treatment programs, vital statistics, facility and 
community-based pregnancy outcome data, antenatal and postpartum care data
•	 Expand and strengthen pregnancy registries, birth defects surveillance, and post-
consumer pharmacosurveillance to identify adverse outcomes of ART on maternal and 
neonatal health
•	 Improve and validate verbal autopsy tools and promote the use of validated methods and 
virtual platforms (such as INTERVA) for verbal autopsies of maternal deaths
•	 Include nested studies on maternal health within large scale intervention studies, 

including in the context of implementation science funded by PEPFAR. 

o	 Include verbal autopsies of maternal deaths in the context of other studies. e.g in 
the context of large-scale community clustered randomized controlled trials which 
are exploring the impacts of widespread HIV-testing and early initiation of ART. 
o	 For instance a nested study on maternal health within the SEARCH (Sustainable 
East Africa Research in Community Health) Study being implemented in 50 
communities in Kenya and Uganda and which includes extensive documentation 
of all deaths. 
o	 Inclusion of questions on pregnancy status and maternal morbidity and mortality 
in facility and community-based surveys would generate valuable information 
about the relationships between timing of treatment initiation, ART and maternal 
health. 
o	 Adding autopsies and verbal autopsies of maternal deaths in a selection of 
intervention communities could generate improved cause of death data. 
•	 Advocate for the inclusion of measures of maternal health, including calculations of 
maternal morbidity, in periodic population-based studies and other research addressing 











To better understand the consequences of increased availability of antiretroviral treatment 
for women living with HIV of reproductive age and further elucidate relationships between HIV
status and maternal health, the expert meeting proposed a multicenter network study which 
would include both urban and rural facilities and allocate sufficient resources for outreach 
workers in order to reduce loss to follow-up of pregnant and postpartum women, both those 
living with HIV and those who are not. The study would use a common data collection tool and 
include detailed death investigation. This research could also provide a forum to improve verbal 
autopsy tools by using autopsy or minimally invasive autopsy to validate results and to generate 
and validate new questions and algorithms. In addition, cohort studies that include pregnant 
women who are both living with HIV and HIV-negative and studies that use a stepped wedge 
design as different options for providing ART are rolled out can help address some of the 
unanswered questions about HIV disease progression during pregnancy, effects of HIV on 




        














Research Priority 2: Integrating Health Service Delivery to Address
Maternal Health and HIV
Integration is a process that occurs at different levels of the health system (national, 
regional, district, health facility) and in relation to key health system functions (e.g. governance, 
financing, planning, service delivery, monitoring and evaluation, demand generation) (WHO 
2008, Atun, Lazarus et al. 2010). Research Priority 2 considers integration at the service delivery 
level. The focus is operational integration of critical components of MCH and HIV services, 
preferably by providing a single point of access or adding a priority component to an existing 
service rather than partial integration through referrals to other services even if they are located 
at the same facility. The promise of integrated service delivery is that meeting women’s multiple 
health needs at a single point-of-care, possibly during a single visit and potentially by the same 
providers, could optimize women’s contact with the health system and more effectively utilize
scarce human and financial resources. The danger of integration is that providing additional 
services could prove to be an excessive burden on already under-resourced health systems. In 
addition, integration should not dilute the specialised skills needed to deliver each health care 
component. While, as discussed in greater depth below, research suggests some benefit to MCH 
and HIV service integration and different countries have significant experience with service 
integration, there is surprisingly little high quality data to guide policy and practice. Studies on 
the impact of adding another component to integrated MCH and HIV service delivery are even 
more limited. This situation presents both a need for and an opportunity to conduct high quality 
implementation research and evaluation. 
As well as recommending program evaluation and intervention research on provision of 
integrated MCH and HIV services, the expert meeting prioritized the following interventions for 
research and evaluation: prevention and treatment of malaria; diagnosis and treatment of 
tuberculosis; and two reproductive health services—preconception counseling and postpartum 
contraception for women living with HIV. Implementation science is urgently needed. It can be 
employed to test how these program components can be integrated with HIV and MCH services 
and assess i) the impact on human resource needs and measures of coverage and proximate 











    













satisfaction of both service users and providers); and ii) the effect on intermediate health 
outcomes (such as prevention of unintended pregnancy and maternal morbidity and mortality). 
Priority Research Questions
•	 What are the most effective models for integrating HIV testing, treatment and care with 
antenatal, intrapartum, and postpartum services?
•	 How can additional critical interventions—specifically screening, prophylaxis and 
treatment for malaria and tuberculosis, postpartum family planning, and preconception 
counseling—be integrated into the continuum of MCH and HIV services while 
maintaining quality, effectiveness and coverage?
Key Outcomes and Variables
•	 Health outcomes: clinical effectiveness of different interventions with integration, 
maternal morbidity and mortality, pediatric HIV infection, and sexual HIV transmission. 
•	 Health systems: national policies and budget allocation,  process indicators to assess 
coverage and quality of care (including uptake of MCH and HIV services), satisfaction 
and retention of healthcare workers and service users, human resources needed to 
delivery interventions (ratio and cadre of providers to service users, skill level), cost-
benefit and cost-effectiveness.
Integrated HIV and MCH Service Delivery
A systematic review of integrating HIV services into MCH, neonatal, nutrition, and 
family planning care found that integration generally improved health outcomes, as well as 
coverage and quality of services (Lindegren, Kennedy et al. 2012). Another systematic review 
which looked only at the impact of implementation or intensification of PMTCT programs on the 
provision of other MCH services found generally positive results. There were beneficial 
synergies in terms of increased STI prevention (including syphilis screening and treatment) and 
early childhood immunization (Nutman, McKee et al. 2013). Depending on the study, offering
PMTCT was reported to have positive and negative results for the provision of antenatal, 
intrapartum, delivery care, family planning and nutritional supplementation (Nutman, McKee et 
al. 2013). For instance, of twelve studies of the effect of implementation of PMTCT on antenatal 
care attendance, ten studies reported increased attendance and two reported decreases in the 
number of care visits (Nutman, McKee et al. 2013). Similarly, of four studies of implementation 
of nutritional counseling and provision of supplements, three found improvements and one found

















it is not possible to draw definitive conclusions, but in general it seems that implementing 
PMTCT tended to strengthen delivery of other maternal and child health services (Nutman, 
McKee et al. 2013). However, the impact of providing additional HIV-related services in MCH 
care needs to be closely monitored. A case in point comes from a recently published Tanzanian 
study which found that adding HIV-diagnosis and referral for mothers and children during 
routine immunization visits resulted in stable or increased rates of immunizations at urban clinics 
but was associated with an important decline in the number of immunizations performed at rural 
sites (Goodson, Finkbeiner et al. 2013). 
With respect to the provision of ART in MCH services, there is relatively little 
information in the peer reviewed literature about how integrated vs. stand-alone provision of 
PMTCT services impacts on coverage of ART or health outcomes (Tudor Car, van-Velthoven et 
al. 2011, Azman Firdaus, Spaulding et al. 2013). One Zambian study compared provision of 
CD4 testing and ART for PMTCT in the ANC clinic versus urgent referral to the HIV clinic 
located in the same building. The offer of CD4 testing and ART in ANC doubled the proportion 
of treatment-eligible women initiating ART for their own health during pregnancy, but rates 
were still low with only 33% of the women at the integrated site and 14%  of the women who 
were referred initiating treatment; there was no difference in rates of retention in treatment at 90 
days (Killam, Tambatamba et al. 2010).  A cross-sectional South African study which brought 
HIV providers to ANC clinics to provide ART and CD4 counseling reduced delays from the time 
of HIV diagnosis to treatment initiation from a median of 56 days to 37 days (van der Merwe, 
Chersich et al. 2006). 
While not a comparative study, Malawi’s Option B+ Program integrated ART into ANC 
services and began initiating all pregnant and breastfeeding women living with HIV on ART 
without CD4 testing, which resulted in a 748% increase in the number of pregnant and 
postpartum women beginning ART; over a fourteen month period, pregnant and postpartum 
women went from 5% to 35% of all new ART initiations (Chimbwandira, Mhango et al. 2013). 
Offering point-of-care CD4 testing alongside HIV testing in antenatal care may result in 
similarly positive outcomes. A pilot program in South Africa which offered point-of-care CD4 





















of treatment eligible women began ART, with 91% of them beginning ART the same day they 
had the point-of-care testing (Myer, Zulliger et al. 2012). 
A 2013 review of integration of provision of ART in ANC or MCH settings showed 
positive impacts on adherence to ART during pregnancy, improved ART initiation, and retention 
in care; no statistically significant effects were found for mortality, morbidity, immunologic 
response, uptake of infant HIV testing, number of infants testing positive for HIV, or satisfaction 
with care (Azman Firdaus, Spaulding et al. 2013). Delivery of ART in ANC services increases
uptake, but most studies have not reported specifically on morbidity and mortality outcomes for 
pregnant and postpartum women or long-term retention in care. 
Research in the peer reviewed literature about how to best integrate other interventions, 
such as postpartum contraception or TB screening and treatment, into services that are already 
providing some aspect of integrated HIV care for pregnant and postpartum women is almost 
nonexistent (Tudor Car, van-Velthoven et al. 2011). Research which evaluates the effectiveness, 
costs, and satisfaction of users and healthcare workers with integrated service delivery is 
urgently needed. 
Research Questions
•	 What are the advantages and disadvantages of integrating services, in terms of the quality 
of care, clinical effectiveness, and coverage of each of the specific health services (e.g 
contraception counseling and provision; safer conception counseling; malaria screening 
and treatment, tuberculosis screening and treatment)?
•	 What is the optimal setting (point on the continuum of care) to deliver each service?
•	 How does service integration impact the uptake, linkage and retention of pregnant and 
postpartum women in HIV, MCH and related services?
•	 What human resources are needed to effectively and safely deliver the intervention to 
pregnant women and women of reproductive age in areas of high HIV prevalence?
•	 What is the effect of providing integrated services on maternal morbidity and mortality, 


















•	 What are the costs and cost-effectiveness of integrated services? Are there efficiency 
gains for both the woman and the health system that would improve uptake and 
sustainability?
Prevention and Treatment of Malaria
Implementation of the interventions to prevent malaria among pregnant women—
Intermittent Preventive Treatment of Malaria in Pregnancy (IPTp) and insecticide treated bednets 
(ITN) are insufficient in sub-Saharan Africa. Review of national survey data from 27 countries 
(2009-2011) found that  even though the median coverage for at least two ANC visits was 85%, 
the median coverage of two doses of SP for IPTp was 25% (Hill, Hoyt et al. 2013). Similarly, 
despite national policy commitments to provide ITNs to pregnant women in all malaria-endemic 
countries, data from 37 countries reported a median bednet use of 35% (personal communication 
with A.M. van Eijk cited in Hill, Hoyt et al. 2013). A recent study from Kenya found that 59% of 
women who attended ANC and were not taking cotrimaxole received a single dose of SP, and of 
the 90% who returned for at least one more prenatal visit, 57% received a second dose, only 9% 
reported receiving a third dose; coverage with bed nets, which were mostly provided through the 
ANC was 89%. No differences in SP use or bed net coverage were reported by HIV-status (Hill, 
Dellicour et al. 2013). Low levels of implementation of multiple doses of SP may be particularly 
deleterious for pregnant women living with HIV as a recent Cochrane review found that women 
with HIV can benefit from monthly SP (Mathanga, Uthman et al. 2011). Key barriers to the 
provision of IPTp and ITN during pregnancy in sub-Saharan Africa include unclear policy and 
guidance; healthcare system issues (for example stock-outs and user fees); and barriers related to 
the health facility and health workers, including poor organization and confusion about dosing 
(Hill, Hoyt et al. 2013). 
Information about the integration of prevention and treatment for malaria with HIV 
treatment and care is scarce. A study of PEPFAR-funded programs in six Ministry of Health 
primary care clinics in Uganda found that implementation of the HIV treatment program 
increased testing for malaria, though specific results for pregnant women were not reported 
(Matsubayashi, Manabe et al. 2011).  A study on the acceptability and feasibility of integrated 
malaria and HIV prevention services for pregnant women in Uganda found that women in the 




















   
malaria and that midwives working in the public and private sector need increased support in 
terms of provision of medications, training, and supervision if they are to provide these services 
routinely (Mbonye, Hansen et al. 2010).
Research Questions 
•	 How does the offer of monthly SP to pregnant women living with HIV in prenatal 
care affect coverage of IPTp for HIV-negative pregnant women?
•	 Is monthly SP or cotrimoxazole more effective and safer for IPTp among pregnant 
women living with HIV?
•	 What are the most effective models for harmonization of policy and programmatic 
guidelines which integrate HIV and malaria prevention, diagnosis, and treatment in 
antenatal care?
Diagnosis and Treatment of Tuberculosis:
The WHO recommends a four-part symptom screening algorithm to identify TB among 
HIV-infected people, including pregnant women. However, doubts about the sensitivity and 
specificity of this screening tool among women living with HIV are being raised. A study of
1451 pregnant women living with HIV in Soweto that compared the screening questions to the 
gold standard of liquid sputum culture found that 73% of the women who were culture positive 
did not report any of the symptoms identified in the WHO four-part symptom screen (Hoffmann, 
Variava et al. 2013). Further healthcare provider training in diagnosis and management of 
tuberculosis that may be unmasked as a consequence of antiretroviral treatment and closer 
monitoring of pregnant women starting ART for Immune Reconstitution Inflammatory 
Syndrome (IRIS) may be indicated until improved screening techniques are available. Screening 
techniques with improved sensitivity and lower cost diagnostic tests are urgently needed to 
identify TB among HIV-infected pregnant women in resource limited settings (Mathad and 
Gupta 2012, Hoffmann, Variava et al. 2013).  Cost-reductions in new diagnostic technology 
(Expert MTB-RIF) that can provide confirmation of tuberculosis within two hours at the point of 
care, including identifying multidrug resistant TB, could make a significant contribution to 



















Technical challenges for TB diagnosis among pregnant women living with HIV are 
compounded by health systems challenges. In South Africa, where TB screening is 
recommended as a routine part of prenatal care, uptake and provision of preventive treatment has 
been suboptimal. For instance, only 66% of pregnant women living with HIV accepted screening 
for TB in the context of PMTCT during a 2003 study in two Soweto clinics (Kali, Gray et al. 
2006). A follow-up study which recruited women living with HIV and HIV-negative women at 
six antenatal clinics which were also providing PMTCT was only able to screen 45% for TB; 
nurses did not investigate 15% of suspected TB cases (Gounder, Wada et al. 2011). In 2008, the 
province of KwaZulu-Natal reported that 55% of pregnant women living with HIV were 
screened for TB symptoms, but none were provided preventive treatment (Uwimana, Jackson et 
al. 2012). 
Pregnant women may be reluctant to undergo another screening test and face diagnosis 
with tuberculosis, particularly if they have been recently diagnosed with HIV (Kali, Gray et al. 
2006). Poor morale among healthcare providers and resistance to taking on new responsibilities 
without additional payment in antenatal clinics that are already providing PMTCT was identified 
as a barrier to integrating TB screening in Soweto, South Africa (Gounder, Wada et al. 2011). In 
KwaZulu-Natal, stakeholders stated that the legacy of vertical programs (financing, targets, 
hierarchy), different ideas about how to integrate services, and human resource limitations (in 
terms of staffing levels, skills, and scope of practice) were barriers to providing integrated 
TB/HIV/PMTCT services (Uwimana, Jackson et al. 2012).  An acceptability study of TB  
screening and treatment as part of ANC in Malawi found that clients and healthcare providers 
were concerned that providing integrated services would negatively affect staff workloads and 
waiting times (Sangala, Briggs et al. 2006). To date there is little evidence on the quality of care 
before and after introduction of TB screening into ANC/PMTCT services, quantitative measures 
of the impact on workload, or maternal mortality or morbidity (Tudor Car, van-Velthoven et al. 
2011).
Research Questions
•	 What are the best screening questions and diagnostic methods for improving 










     






                                                
           
              
   
    
•	 How do educational programs for healthcare providers and counseling for pregnant 
women to inform them about the safety of IPT during pregnancy impact on coverage?
•	 What are the barriers to acceptance of TB screening among women with a recent 
HIV-diagnosis?
•	 Does training providers working in prenatal care to identify and manage IRIS 
improve clinical outcomes in areas with a high prevalence of HIV/TB co-infection?
Reproductive Health of Women with HIV: Pre-Conception Counseling and 
Postpartum Contraceptives for HIV-Positive Women
Meeting unmet need for family planning in sub-Saharan Africa could make an important 
contribution to improving maternal health. In 2008, the estimated maternal mortality ratio in sub-
Saharan Africa was 596 per 100,000 live births, contraceptive prevalence was 22% and the 
proportion of maternal deaths averted by contraceptive use was estimated at 32%. In contrast, 
among low- and middle-income countries as a group, the maternal mortality ratio was 273, 
contraceptive prevalence was 63%, and 44% of maternal deaths were estimated to be averted by 
contraceptive use (Ahmed, Li et al. 2012). In 2012 it was estimated that in sub-Saharan Africa 53 
million women who wanted to avoid pregnancy were not using a contraceptive method, i.e. had 
unmet need for modern contraceptive methods (Darroch and Singh 2013). Maternal mortality is 
affected by multiple social, economic, and health systems factors beyond contraceptive access 
and use, yet these estimates suggest that important gains in eliminating preventable maternal 
mortality could be achieved if more women used modern contraceptives. For women living with 
HIV, preventing unintended pregnancies will promote women’s health and is also a cost-
effective way to prevent new pediatric HIV infections (Reynolds, Janowitz et al. 2008). In fact, 
modeling studies suggest that it will not be possible to reach the 2015 targets for reducing new 
pediatric HIV infections in high-burden countries unless unmet need for family planning among 
women living with HIV is eliminated (Mahy, Stover et al. 2010).11 Yet, unmet need for 
11 The target is to reduce new pediatric HIV infections 90% by 2015 in 25 high-burden African countries. Modeling
suggests that to reduce new pediatric HIV infections 73%, in addition to providing 90% of HIV-positive pregnant



















contraception among women living with HIV in sub-Saharan Africa is high, with 66-92% of 
women reporting not wanting another child (now or ever), but only 20-43% using contraception 
(Sarnquist, Rahangdale et al. 2013). 
Reports about the influence of HIV status on reproductive desires vary, with some studies 
showing no difference in reproductive intentions between people with HIV and the general 
population, and others finding that women living with HIV are less likely to desire more children 
than their HIV-negative counterparts (Nattabi, Li et al. 2009). There is evidence that 20% to 50% 
of people with HIV desire more children after the diagnosis (Matthews, Crankshaw et al. 2013). 
A recent meta-analysis which mostly drew data from studies conducted in sub-Saharan Africa 
associated wanting more children with not having a child and being under thirty years of age 
(Berhan and Berhan 2013). In addition to these two factors, being a man, having fewer children, 
good (self-reported) health status, and broader cultural, spousal and familial norms and 
expectations about reproduction and family size have all been associated with desiring children 
following an HIV diagnosis (Nattabi, Li et al. 2009). 
Better health status associated with ART use can be expected to increase the biological 
capacity of women living with HIV to become pregnant, and may also increase their desire to 
have more children. Being on ART has been associated with increased fertility desires (Myer,
Rebe et al. 2007, Cooper, Harries et al. 2007, Cooper, Moodley et al. 2009) and initiating ART 
has been associated with a higher incidence of pregnancy (Myer, Carter et al. 2010, Kaida, 
Matthews et al. 2013). Whether these pregnancies are intended or unintended, significant 
numbers of women in HIV treatment programs become pregnant (Cooper, Moodley et al. 2009,
Homsy, Bunnell et al. 2009, Kaida, Laher et al. 2010, Kaida, Matthews et al. 2013). For instance, 
in the context of the multi-country MTCT-Plus initiative, which provided women living with 
HIV with contraceptives but did not have a special reproductive health counseling protocol, the 
incident pregnancy rate was 7.8 per 100 person years [range 3.3 in South Africa to 21.7 in 
Rwanda]; using condoms for contraception was associated with a higher pregnancy rate than 
using non-barrier modern contraception (Myer, Carter et al. 2010). Women with HIV require 
health services to prevent unwanted pregnancies and to permit safe conception, healthy 



















   
  
counseling and pregnancy prevention services for women living with HIV into MCH and HIV 
services. 
Preconception Counseling and Safe Conception for Women Living with HIV
People with HIV often desire a child or more children (Kaida, Laher et al. 2011,
Matthews, Crankshaw et al. 2013, Cooper, Moodley et al. 2009) and 20-60%  have an HIV-
negative partner (Anderson 2013). In sub-Saharan Africa, women are the HIV-positive person in 
about half of discordant partnerships (Eyawo, de Walque et al. 2010). In this context, it is 
difficult to overstate the revolutionary potential of “treatment as prevention”—the capacity of 
ART to suppress viral load and radically reduce sexual and mother-to-child transmission —for 
the reproductive lives of women living with HIV in sub-Saharan Africa (Volmink, Siegfried et 
al. 2007, Attia, Egger et al. 2009, Cohen, Chen et al. 2011). The WHO recommendation that 
people with HIV who have serodiscordant partners be given the option of immediately beginning 
ART to reduce sexual transmission can facilitate safe conception for serodiscordant couples and 
will contribute to preventing new HIV infections among men and women (WHO 2013).  
Women and men with HIV in resource constrained settings can conceive a child while 
reducing transmission risks to an HIV-negative partner by diagnosing and treating other sexually 
transmitted infections (STIs), the person with HIV adhering to their ART regimen and having an 
undetectable viral load and reducing the instances of unprotected sex through timed intercourse 
or home-based insemination (Chadwick, Mantell et al. 2011, Matthews, Smit et al. 2012). It is 
reasonable to conclude that the HIV-negative partner taking pre- or post-exposure prophylaxis 
can further reduce the risk of HIV transmission, but more research is needed (Bekker, Black et 
al. 2011, Vernazza, Graf et al. 2011). Two studies of “natural conception” in high-income 
settings among serodiscordant couples in which the person with HIV had an undetectable viral 
load recorded no instances of transmission to the HIV-negative partner in a total of 129 
pregnancies and only one instance of MTCT (Vernazza, Graf et al. 2011, Barreiro, del Romero et 
al. 2006). Nevertheless, these findings should be interpreted cautiously as the numbers were 
small and because HIV has been identified in the semen, follicular fluid and endometrial lining 













unlikely under these circumstances, it remains a possibility (Bekker, Black et al. 2011, Mounzer 
and DiNubile 2013).
To enable people with HIV to make informed choices and benefit from “treatment as 
prevention” for reproductive ends, healthcare providers must know about these interventions and 
communicate clearly with people with HIV. The track record of HIV services in both rich and 
resource-constrained countries for providing a supportive, non-stigmatizing environment for 
women living with HIV to make reproductive decisions has been middling at best. Most women 
living with HIV do not broach the issue of reproduction with providers before getting pregnant.  
If providers do not initiate a non-stigmatizing conversation about reproductive intentions, this 
communication between provider and client tends not to happen at all (Cooper, Harries et al. 
2007, Cooper, Moodley et al. 2009, Squires, Hodder et al. 2011, Finocchario-Kessler, Bastos et 
al. 2012, Finocchario-Kessler, Mabachi et al. 2012). Research about healthcare providers’ and 
PLHIV’s knowledge and communication about “treatment as prevention” and associated 
reproductive intentions, behaviors, and outcomes is just beginning. A qualitative study with men 
and women living with HIV in Durban South Africa found that most couples did not know how 
to reduce the risk of sexual HIV transmission and still become pregnant (Matthews, Crankshaw 
et al. 2013). 
Implementation research is urgently needed about i) how to integrate pre-conception 
counseling interventions into HIV care (including information about knowledge, attitudes and 
practices of PLHIV and providers); ii) the acceptability and evaluation of guidelines for safer 
conception; iii) how best to provide pre-exposure prophylaxis (PReP) to support safe conception;
and iv) the health outcomes associated with provision of these interventions—specifically rates 























   
 
Research Questions 
Recognition that ART allows safer conception for people living with HIV and their 
sexual partners is relatively recent. Formative and implementation research is needed on models 
of care for preconception counseling. There are multiple outstanding research questions, such as: 
•	 What is the efficacy and acceptability of biomedically safer conception methods 
including treatment as prevention, pre-exposure prophylaxis, and male circumcision 
in the context of desired conception?
•	 What safer conception policies and guidelines are feasible to introduce into policy, 
programs and services for serodiscordant and concordant couples living with HIV?
•	 What are the most effective means of engaging policy-makers and other key 
stakeholders to move towards implementation of what is currently feasible?
•	 What do people with HIV and health care providers know and communicate about 
serodiscordance and safer conception methods, including treatment as prevention?
•	 What is the best mix of providers and program models for providing to 
preconception counseling?
•	 When and where should preconception counseling be offered?
•	 What counseling and support services (such as peer support groups and networks of 
people with HIV) are feasible and support safe conception and pregnancy among 
serodiscordant couples in resource-constrained settings?
•	 How will knowledge about treatment as prevention and pre-exposure prophylaxis, 
and information provided during preconception counseling, affect reproductive 
















   
 
 
Integrated Provision of Contraceptives for Women Living with HIV
Integration of family planning and HIV services and behavioral interventions to promote 
contraceptive use among women living with HIV has had generally positive results. While the 
evidence-base is not abundant, uptake of contraceptives, condom use, measures of service 
quality, and health outcomes—measured by  incident pregnancies and sexually transmitted 
infections—have all been positively affected by integration (Brou, Viho et al. 2009, Ngure, 
Heffron et al. 2009, Spaulding, Brickley et al. 2009, McCarraher, Vance et al. 2011, Lopez, 
Hilgenberg et al. 2013, Wilcher, Hoke et al. 2013). That information and access fuels demand for 
contraceptives among people living with HIV is suggested by the 99% of couples adopting a 
modern method in a Zambian study of contraceptive use (Wall, Vwalika et al. 2013). The 
feasibility and positive impact of increasing information and access has been identified in several
African studies which found that strengthening referrals from HIV clinics resulted in increased 
attendance at Family Planning (FP) clinics (Wilcher, Hoke et al. 2013). For instance relatively 
small program modifications in  monitoring and evaluation and training in the context of a 
national PEPFAR program boosted referrals to FP clinics in Ghana (Chabikuli, Awi et al. 2009). 
Providing contraceptive counseling and methods to women in HIV services has been shown to 
be even more effective. A Kenyan clinical trial which trained HIV staff on FP and provided 
couple counseling and free methods onsite rather than referring to FP services observed a 
substantial increase in use of non-condom contraception by women with HIV (OR 6.4) (Ngure, 
Heffron et al. 2009). In this study, reported condom use was 88% at last sex and overall 
pregnancy incidence declined (Ngure, Heffron et al. 2009). A more recent cluster-randomized 
trial in Kenya which compared provision of effective contraceptive methods within HIV services 
at the twelve intervention sites with referral to family planning services at the six control sites 
found that women in the intervention clinics were significantly more likely to use effective 
contraceptive methods (OR 1.81) and the decrease in condom use at intervention sites was non-
significant (OR 0.64) (Grossman, Onono et al. 2013).  The intervention was found to be a cost-
efficient way to provide contraceptives to women living with HIV (Shade, Kevaney et al. 2013).
As this brief review illustrates, most interventions have focused on strengthening referrals 




   
 
  






   
  
                                                
              
               
               
planning counseling and contraceptives into postpartum services for women with HIV is a 
relatively neglected area of research. 
Additional research is also needed on the safest and most acceptable contraceptive 
methods for women living with HIV. The World Health Organization recommends a full range 
of contraceptive methods for women with HIV (depending on immune status and ART regimen) 
(WHO 2012a).12 The weight of available evidence suggests that hormonal contraceptives do not 
hasten disease progression among women with HIV (Heffron, Mugo et al. 2013, Phillips, Curtis 
et al. 2013). However, evidence suggesting that there may be increased risk of female-to-male 
transmission when women use progestin-only injectable contraceptives remains a concern, and 
more research is needed (Heffron, Donnell et al. 2012, Polis, Phillips et al. 2013, McCoy, Zheng 
et al. 2013). More clinical research on the best contraceptives for women with HIV, including 
long acting reversible contraceptive methods (LARC) other than injectable contraceptives, is 
needed. Several studies on LARC are planned or underway. 
Equally important is implementation research to assess attitudes and acceptability of 
currently available and new contraceptive methods among women with HIV (both those who are 
taking ART and those who are not), their intimate partners and health service providers, and to 
demonstrate how to optimally provide contraceptives to women living with HIV, particularly 
during the postpartum period. While recent reviews provide reassurance about the use of 
hormonal contraceptives and disease progression, concerns about HIV acquisition and injectable 
contraceptives, drug interactions between some hormonal contraceptives, medications to treat 
tuberculosis and antiretroviral treatment (WHO 2010b) and the resulting complexity of choosing 
the best contraceptive method has caused worry  and confusion among healthcare providers, 
community networks, and women living with HIV (Athena 2012). Similarly, more information 
about why women living with HIV do and do not adopt dual protection (condom + another 
contraceptive method) and evaluation of models of service delivery that are effective at 
increasing use of dual protection are needed. 
12There is continued uncertainty about whether or not the use of progestin-only injectable contraceptives increase
women’s risk for HIV acquisition, with some studies finding an association and others not (Heffron, Donnell et al.













International research also documents that women living with HIV continue to 
experience reproductive rights abuses which range from omission of information and services to 
coercive sterilization and abortion (Ahmed, Roseman et al. 2012, Kendall 2009, Kendall 2013, 
Landolt, Phanuphak, et al. 2012, Mallet and Kalambi 2008). Implementation research on stigma-
reduction for healthcare providers and rights-based approaches to ensure women with HIV have 
the needed information and access to services to make and implement informed, autonomous 
contraceptive choices is a priority. 
While modeling studies have found that preventing unintended pregnancies among 
women with HIV is a highly cost-effective means to prevent new pediatric HIV infections, little 
information is available about the cost and relative cost effectiveness or cost benefits of 
integration of contraception into HIV programs in the postpartum period, or comparative 
assessment of health outcomes such as incident pregnancies, HIV or other STIs (Spaulding, 
Brickley et al. 2009, Lopez, Hilgenberg et al. 2013). Nevertheless, it is heartening that a recent 
cluster-randomized trial in Kenya found integration of contraceptives into HIV clinic services to 
be cost-efficient (Shade, Kevaney et al. 2013).  Many of the studies available were conducted in 
the context of clinical trials and thus do not address the mix and level of human resources needed 
to provide integrated services in the context of routine care. Wilcher and colleagues note that the 
effects of integration of contraceptive referral and provision into public sector clinics has been 
more modest than for interventions which took place in the context of clinical trials, emphasizing 
the need for implementation research (Wilcher, Hoke et al. 2013). Impact of the provision of 
contraceptives in the postpartum period on subsequent maternal morbidity and mortality among 




















   
 
   
Research Questions
• What models of counseling and service delivery increase accessibility and uptake of 
contraceptive methods by women with HIV, and simultaneously ensure respect for 
reproductive rights?
• What is the role of community and community-facility collaborations in expanding 
access and uptake of contraceptives among women living with HIV?
• How can contraceptives be most effectively provided in PMTCT and MCH settings and 
within HIV care and treatment?
• What contraceptives are most effective and safest for women living with HIV who are 
taking ART?
• What are the possibilities of expanding LARC other than hormonal injectable 
contraceptives for use among women living with HIV? What is the status of their 
approval (e.g. implants) and availability in different country contexts?
• What are the attitudes of women with HIV, male partners and healthcare providers 
toward currently available and alternative longer term contraceptive methods?
• How can dual method use (condom + contraceptive) be increased among women living 
with HIV and their sexual partners?
• How do we increase postpartum and post-abortion contraceptive uptake and retention?
• Are postpartum immunization visits an optimal time for providing family planning 

















                                                
              
       
  
             
               
        
              
      
 
Human Resources Shortages and Workload
There are critical human resource shortages in all areas of health care throughout Africa. 
Absolute shortages are compounded by inequitable distribution between urban and rural areas, as 
well as heavy workloads, insufficient training, weak management and low staffing ratios which 
increase stress and burn-out for health workers, contributing to poor quality care (Kieffer and 
Kiragu 2012). The lack of human resources available to provide HIV care and PMTCT are 
illustrative of the severity and consequences of these shortages which are also present in other 
areas of MCH service provision and across the health system. For instance, an estimation of the 
human resources needed to deliver universal coverage of ART in sub-Saharan Africa by 2017 
found that this could only be achieved if the population of health workers doubled each year over 
a decade and factors such as out-migration were kept to a minimum (Barnighausen, Bloom et al. 
2007). A modelling study which looked at the financial and human resources needed to provide 
recommended interventions for maternal and child health in the context of PMTCT13 in seven 
sub-Saharan African countries found that only three countries had sufficient funds (mostly from 
foreign aid) and only one (Zambia) had sufficient human resources to scale up the interventions 
by 2010 and sustain them to 2015 (Nakakeeto and Kumaranayake 2009). In 2012 the United 
Nations Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant 
Women, Mothers and Children stated bluntly that at the present time there are simply not enough 
health workers in the 22 countries with the highest burden of mother-to-child HIV transmission 
to meet the goals of the Global Plan for the Elimination of  Mother-to-Child Transmission of 
HIV and Keeping Their Mothers Alive (Kieffer and Kiragu 2012).14 
13 HIV testing and counselling of pregnant women in ANC, provision of antiretroviral and cotrimoxazole
prophylaxis to HIV-infected women, cotrimoxazole prophylaxis to HIV-exposed infants, and provision of family
planning to people with HIV.
14 The goals are to reduce the number of new HIV infections among children by 90% and the number of AIDS-
related maternal deaths by 50% with the following actions: reducing HIV incidence among women, eliminating
unmet need for family planning among women with HIV, providing antiretroviral prophylaxis to 90% of women
living with HIV during pregnancy and breastfeeding, and ensuring that 90% of women who need it stay on




















There is some evidence that the lack of adequate numbers of healthcare providers with 
the needed skills constrains the successful implementation of PMTCT. For example, a study of 
PMTCT in 15 sub-Saharan African countries associated moderate ANC activity (30-100 women 
attending ANC services per month) with lower coverage of Sd-NVP. The authors suggest that it 
may be more difficult for medium-sized facilities to adjust to the increased workload demanded 
by PMTCT (Audureau, Kahn et al. 2013). Likewise, a qualitative study which tracked 
implementation of PMTCT in four South African clinics identified missed opportunities for 
testing of pregnant women because one nurse was usually responsible for providing all 
counseling and related HIV services in PMTCT, as well as performing their regular duties. 
Nurses tried to control their workload by only providing a certain number of HIV counseling
sessions per day and/or only working a certain number of hours on HIV counseling. Pregnant 
women coming to the clinic in the evening or on weekends would not be counselled and tested;
if the “PMTCT nurse” was ill or absent, no services were provided (Sprague, Chersich et al. 
2011).
In the case of task shifting to lay counselors, irregular payment and consequent 
absenteeism limited effectiveness (Sprague, Chersich et al. 2011). Similarly, in Uganda, 
qualitative interviews found that nurses and midwives providing HIV testing to pregnant women 
in ANC perceived that their workload was too heavy and many had other duties (medical 
histories, physical exams, postpartum care, and family planning counseling). To cope, midwife-
counselors employed the following strategies: not taking lunch or breaks, streamlining 
counseling for HIV-negative women to have more time with women living with HIV, or 
including post-test information in the group pretest session in order to shorten individual post-
test counseling sessions (Medley and Kennedy 2010). In short, these findings suggest, not 
surprisingly, that the quality of antenatal counseling for both women living with HIV and HIV-
negative women was negatively impacted by limited human resources. Finally, while a study of 
39 facilities in Zambia found that coverage of key services like ANC, childhood immunization, 
and family planning increased as ART provision and PMTCT were scaled up, they also found 
that provision of HIV services increased workloads and that the few available staff were taking 
on additional work, especially in small rural health facilities (Brugha, Simbaya et al. 2010, 














This discussion of challenges related to human resources associated with the provision of 
HIV testing and treatment in the context of prenatal, intrapartum and postnatal care exemplifies 
some of the considerations which must be taken into account when contemplating integration of 
HIV and MCH services, and the inclusion of additional program components such as screening 
and treatment for malaria and tuberculosis and preconception counseling and family planning for 
women with HIV. 
Task Shifting to address Human Resource Shortages and Workload Issues
For all of the health interventions identified by the expert group as priorities for 
integration, there are studies which suggest that task shifting may be a promising strategy to 
address human resource shortages and workload issues: provision of ART (Mdege, Chindove et 
al. 2013), screening and treatment of tuberculosis (Gabriel and Mercado 2011, Zwarenstein, 
Fairall et al. 2011, Park, Magut et al. 2012), prevention and treatment of malaria (Rao, 
Schellenberg et al. 2013), and delivery of family planning services (Malarcher, Meirik et al. 
2011, Janowitz, Stanback et al. 2012). Indeed, many countries are already implementing task 
shifting strategies for a variety of functions. Checklists, standardized patient record forms, other 
job aids, use of mobile technologies, and continued training, support and supervision are needed 
components for successful task shifting. Care must be taken to avoid intolerable additional work 
pressure on some categories of health workers due to task shifting. Attention is needed to 
additional human resource needs which result from increased number of people with HIV 
accessing treatment and care in response to a lower CD4 threshold for beginning ARTs and the 
implementation of Option B+. Further, while the available evidence on task shifting is promising 
it does not specifically refer to pregnant and postpartum women living with HIV. The skill level 
and optimal provider mix needed to deliver the possible permutations of the needed interventions 
safely and effectively remains an important research gap. Provision of integrated services may 
require a team approach. The World Health Organization has recently released guidance on the 
recommended skill-level for health workers providing contraceptives,  antenatal, intrapartum, 
postpartum and neonatal care (WHO 2012c). Similar guidance on the requisite skills and staffing 














tuberculosis, and the reproductive health of women with HIV during pregnancy and postpartum 
would assist policymakers and administrators.  
Research Questions
•	 What skills, optimal provider mix, and staffing levels are needed to deliver health 
services which integrate MCH and HIV care, particularly in the antenatal and postpartum 
period?
•	 What human resources are required to provide other crucial services such as prevention, 
diagnosis and treatment of malaria and tuberculosis and provision of reproductive health 
services using the platform of antenatal, intrapartum, and postpartum care? 
•	 What is the effect of task shifting on uptake and quality of care?



























Research Priority 2: Moving the Research and Evaluation Agenda Forward
Secondary Analysis
•	 Conduct retrospective or prospective, ecological analysis of countries that have created 
integrated policy guidance and/or implemented integrated service delivery.
•	 Examine what types of integration have occurred, at what levels of the health system, and 
what models have proved successful. 
Improving the Evidence Base and Synergistic Knowledge Generation with Ongoing
Research or Programs 
•	 Advocate for key indicators to be included in the routine program monitoring of relevant 
programs (the Global Fund, STOP TB, PEPFAR, and Saving Mothers Giving Lives, 
among others). For example, PEPFAR reporting could be extremely useful for assessing 
program outcomes if pregnancy/postpartum status of women were available for regularly 
collected indicators. To illustrate, PEPFAR collects HIV and treatment status of pregnant 
women, and monitors TB/HIV integration. If the “pregnant/postpartum” variable were
available in the standard monitoring of TB programs, coverage could be assessed. The 
reasons for collection of current and additional indicator data need to explained to and 
accepted by health service managers and providers and their use understood and 
appreciated for effective and complete data gathering to be achieved. 
•	 Promote inclusion of HIV and ARV treatment status in periodic, large-scale surveys 
(MICS, DHS)
•	 Promote stepped wedge design where an intervention is rolled-out sequentially (either as 
individuals or clusters of individuals) at different points in time. For example, if
resources do not permit universal program implementation, purposive, prospective roll-
out in randomized, community samples with data collection from control communities 
can allow rigorous evaluation. Evaluation is a valuable input for decision-making and, if
results are positive, can generate significant impetus and support for scale-up among 
decision-makers. 
New Research
The critical interventions to be evaluated for integration into the continuum of MCH and 
HIV services are dependent on the country epidemiological, policy context and structure of 
MCH and HIV services. The first step for intervention studies would be to conduct a situation 
analysis to determine the priority of different critical interventions (tuberculosis, malaria,  










and treatment are currently integrated into antenatal, intrapartum and postpartum care (and vice 
versa). Subsequently, assessment of infrastructure, training and staffing needs and optimal point 
for integration along the continuum of care would be determined. After conducting baseline 
research and pilot testing the interventions, a multi-arm research design comparing various 
models for integrated care vs. each other and/or the standard of care would allow the 
identification of preferred integrated models for service delivery. Similarly, a stepped wedge 
design could be used to evaluate integrated models of service delivery. Research should also 
document process measures, such as uptake of HIV and MCH services, retention in care, 




         
   







Research Priority 3: Transforming the Social Context to Improve
Maternal Health
In addition to providing an opportunity for PMTCT, diagnosis during pregnancy must 
support women’s access to treatment for their own health (WHO and UNFPA 2006). 
Unfortunately, pregnant women are less likely to access treatment for their own health than other 
adults. In 2012 only 58% of eligible pregnant women received ART for their own health as 
compared to 65% of the adult population (UNAIDS 2013: 42). This is a promising development 
given that in 2011 only 30% of pregnant women who were estimated to need ART for their own 
health received it, as compared to 54% of the adult population (UNAIDS 2012a: 47). Attention is 
needed to ensure that women who choose to begin treatment remain in care and are supported to 
adhere to treatment. A meta-analysis of adherence during pregnancy and postpartum found that 
while 74% of pregnant women adhered adequately to ART during pregnancy (taking more than 
80% of their ARV doses), only 53% did so in the postpartum period (Nachega, Uthman et al. 
2012). Ensuring uptake and retention in care and adherence to antiretroviral treatment is crucial 
to ensure maximum health benefits of increasing availability of antiretroviral treatment for 
women, their children, and their sexual partners. At the community and national level uptake, 
retention and ART adherence will prevent new HIV infections and delay the development of 
resistance, thereby extending the utility of existing treatment options for individuals and 
contributing to the sustainability of expanded treatment access for national health systems. 
Structural interventions may facilitate women’s uptake and retention in care and directly 
improve health outcomes by modifying social determinants of health. Examples of structural 
interventions include improving women’s socioeconomic status through large-scale poverty 
alleviation programs, for example the Millennium Development Villages and programs of 
conditional and unconditional cash transfers which target women. There are also important 
initiatives to expand healthcare insurance in many low and middle-income countries and provide 
financial incentives for healthcare providers and healthcare users to increase both supply and 
demand of HIV and MCH care. These programs should be evaluated for their impact on 
pregnancy-related morbidity and mortality among women living with HIV and HIV-negative 
women. At the health facility and community level, UNAIDS has identified a series of promising 













   
  
   
 
provision of cotrimoxazole prophylaxis free of charge, ensuring shorter waiting times at HIV 
clinics, point-of-care CD4 testing, decentralization of services and various forms of adherence 
support (peer groups and community adherence clubs, mobile-phone text reminders, diary cards 
and food rations) (WHO, UNICEF et al. 2013: 11). 
While noting the relevance of the initiatives and strategies mentioned above, the expert 
meeting chose to prioritize evaluation of existing interventions that have been shown to modify 
gender norms (reducing gender violence and increasing supportive male involvement), mobilize 
the community to promote maternal health, and increase social support for pregnant and 
postpartum women. The interventions described below have reduced gender violence or 
improved clinical outcomes in maternity care including adherence to PMTCT. Some also show 
promise for improving uptake, coverage, and technical and intrapersonal quality of care through 
greater community oversight and reduction of HIV-related stigma and disrespect and abuse. The 
interventions share a common mechanism of action in that they seek to empower women using 
participatory methodologies and to change the social context by engaging the broader 
community to transform social norms that undermine women’s health. These programs have 
been shown to change individual behaviors, as well as promote policy frameworks and 
institutional practices that support women’s rights and dignity. Research on the impact of 
human-rights based approaches in maternal and child health is urgently needed (Bustreo, Hunt et 
al. 2013, Ferguson and Halliday 2013, Tarantola, Unnithan et al. 2013).
Priority Research Questions
•	 Which community mobilization, peer support, and male engagement interventions 
improve uptake of and retention in HIV and MCH services and promote improved 
maternal health outcomes?
•	 Do interventions which reduce gender violence, HIV-related stigma and discrimination, 
and disrespect and abuse in maternity care reduce maternal morbidity and mortality?
•	 Do these interventions affect proximate outcomes like uptake of HIV and MCH services, 
linkage from diagnosis to ART, retention in care, adherence to ART or disclosure of 
















Key Outcomes and Variables
•	 Key outcomes to be measured include: uptake of HIV and MCH services, linkage from 
HIV diagnosis to treatment, retention in care, antiretroviral adherence, postpartum 
depression, disclosure of HIV status, HIV-related stigma and discrimination, disrespect 
and abuse in maternity care, other health-related quality of life measures, cost-benefit and 
cost-effectiveness.
Validated measures exist for many of these outcomes. For instance, it is recommended 
that ART adherence be measured through a combination of self-report and pharmacy refill data, 
if possible. For self-report, there are different validated measures such as count based measures 
(for example the frequently used recall portion of the AIDS Clinical Trials Group questionnaire) 
or estimation measures such as visual analog scales (where patients mark their estimated 
adherence during a specific time period—for example during the last month), the Swiss Cohort 
Study Adherence Questionnaire, or the Case Adherence Index Questionnaire (Williams, Amico 
et al. 2013). There are several tools to measure post-partum depression, including the Edinburgh 
Postnatal Depression Scale (EPDS) and the Postpartum Depression Screening Scale (PDSS). 
These screening tools have shown sensitivity and specificity, though cultural context and the 
socioeconomic situation must be considered (Zubaran, Schumacher et al. 2010). Health-related 
quality of life measures have been adapted specifically for PLHIV, for example the Medical 
Outcomes Study (MOS-HIV) and Functional Assessment of HIV Infection (FAHI) survey which 
have both been used extensively (Clayson, Wild et al. 2006). Several tools to identify HIV-
related stigma that have been used extensively (see for example The People with HIV Stigma 
Index www.stigmaindex.org). Finally, efforts are underway to define and validate measures for 










Reduce Violence Against Women
The WHO Multi-country study on domestic violence identified that among ever-
partnered women in 15 sites from ten countries, 15 to 71% had experienced physical, sexual or 
both forms of violence from an intimate partner during their lifetime (Garcia-Moreno, Jansen et 
al. 2006). Experiencing sexual and physical violence from an intimate partner has been 
associated with higher HIV prevalence among women attending ANC in South Africa (Dunkle, 
Jewkes et al. 2004). Intimate partner violence (IPV) has been associated with higher rates of 
unintended pregnancy and abortion, both of which put women at risk of maternal morbidity and 
mortality (Pallitto, Garcia-Moreno et al. 2013), especially in contexts where abortion is illegal or 
access is very restricted. Experiencing IPV has been associated with lower rates of skilled birth 
attendance among women in Kenya (Goo and Harlow 2012), pregnancy complications (sepsis, 
bleeding, eclampsia) among Nigerian women (Andersson, Omer et al. 2011), and pregnancy loss 
and induced abortion in Tanzania (Stockl, Filippi et al. 2012). No studies on the relationship 
between experiencing IPV and ART adherence in Africa were identified, but in the United 
States, IPV has been associated with reduced adherence to ART and detectable viral load among 
women living with HIV (Lopez, Jones et al. 2010, Trimble, Nava et al. 2013). Both the IMAGE 
project and the Stepping Stones project were found to reduce IPV, and other risk behaviors for 
HIV transmission and negative gender norms which are drivers of both the HIV and gender 
violence pandemics. 
The IMAGE project implemented in Southern Africa provided micro-finance to the poorest 
women in different communities alongside a participatory curriculum of gender and HIV 
education for the women and other community members. While the intervention was not found 
to significantly reduce unprotected sex with non-spousal partners or HIV incidence, it did reduce 
women’s experience of IPV by half (Pronyk, Hargreaves et al. 2006). At follow-up, levels of 
IPV were maintained at less than half of the baseline in all four intervention villages while they 
stayed the same or increased in the four control villages. The intervention also increased the 
economic well-being of the household, improved measures of women’s empowerment, and 
contributed to better communication about sexuality and more supportive partner relationships 















lead) social groups and to take part in collective action than women in the control villages (Kim, 
Watts et al. 2007). 
The Stepping Stones program, which was originally developed in Uganda and has now been 
implemented in more than forty countries in Africa, Asia, and Latin America, takes a 
participatory gender transformative approach involving critical reflection on gender inequality as 
a means of encouraging safer sexual practices. Peer groups (stratified by age and gender) work 
separately and then together to analyze factors that affect their lives and behavior, and to define 
how they could implement positive change to reduce HIV and AIDS vulnerability in their life 
and community. Program evaluations from India, Gambia, South Africa, Ethiopia, Angola, 
Tanzania, Uganda and Fiji involving 14,630 people have also shown varied but generally 
positive results with reduction in IPV and other behavioral risk factors for HIV acquisition such 
as abusing alcohol and having multiple sexual partners (Skevington, Sovetkina et al. 2013). 
Participation in the Stepping Stones program has also been correlated with increases in HIV 
knowledge and measures of gender equity and reductions in HIV-related stigma (Skevington, 
Sovetkina et al. 2013). The South African randomized controlled trial of the Stepping Stones
program, which measured biological outcomes, had a number of interesting findings. First, the 
study identified a statistically significant reduction in herpes infections among the intervention 
group. Second, while not statistically significant, there were 15% fewer new HIV infections 
among young women in the intervention group (Jewkes, Nduna et al. 2008). 
The interventions mentioned have not been evaluated for their impact on maternal health 
outcomes in areas of high HIV prevalence. 
Research Questions
•	 Do interventions which transform gender norms and reduce gender-based violence reduce 
maternal morbidity and mortality, increase uptake of MCH or HIV services, or improve 




        
 
 
Engage Men in HIV and MCH Services
Male involvement in PMTCT—either by accompanying women to antenatal visits, 
because the woman has shared information about PMTCT and her HIV status with her male 
partner, or because the man has participated in individual and/or couple-testing for HIV— 
supports women to successfully complete PMTCT interventions, as measured by facility 
delivery, infant dosing with ARV, and exclusive infant feeding (Farquhar, Kiarie et al. 2004, 
Conkling, Shutes et al. 2010, Peltzer, Mlambo et al. 2010, Peltzer, Sikwane et al. 2011, 
Kalembo, Zgambo et al. 2013). However, the finding that male involvement improves PMTCT 
outcomes may arise in relationships where men are already supportive of women’s health. 
Promoting men’s engagement through intervention studies has had mixed results.
An intervention which randomized pregnant women to individual voluntary counseling 
and testing (IVCT) for HIV or couple voluntary counseling and testing (CVCT) in Tanzania is a 
cautionary tale about the potentially negative impacts of certain ways of promoting male 
involvement on women’s uptake of services. Half of the women randomized to CVCT did not 
return to the clinic, only 16% completed CVCT, and only 43% of the women randomized to 
CVCT completed HIV testing during pregnancy (either alone or with their male partners) as 
compared to 78% of the women in the IVCT group (Becker, Mlay et al. 2010). Clearly, women’s 
concerns about disclosure of HIV status to male partners needs to be addressed and options for 
confidentiality considered carefully in efforts to promote male engagement. Not requiring male 
involvement as a condition of service provision is critical given that, in many communities in 
sub-Saharan Africa, a significant proportion of pregnant women are single. Finally, interventions 
which seek to involve men must ensure that women’s autonomy, safety and choices are 
respected.
Identifying the most effective models for engaging men in HIV and MCH services to 
promote their own and their female partners’ health is an important research priority. 
Disappointingly, most efforts to involve men in PMTCT have focused narrowly on male HIV 
testing (Sherr and Croome 2012). A wider range of interventions to involve men in pregnancy 
and HIV prevention and care, and which treat men as clients and respond to their reproductive 
and HIV-related health needs as well promoting women’s health, are needed (Brusamento, 





   






successful at engaging men and obtaining high rates of treatment uptake and retention for men, 
women and children is the MTCT-Plus model of “family-focused care” which aims to enroll the 
pregnant woman and other HIV-infected family members. In a cohort from the Ivory Coast, 95% 
of the eligible women began treatment and, of those, 98% were still in care two-years later. 
Additionally, 78% of those living with HIV and more than half of the HIV-negative male 
partners participated in the program and 95% of the male partners on ART and 100% of the 
HIV-positive and HIV-negative children, as well as the HIV negative male partners were still in 
the program at the two year follow-up (Tonwe-Gold, Ekouevi et al. 2009). 
Women’s choice not to disclose their HIV status to male partners can be a barrier to male 
involvement if disclosure is or is perceived to be a condition of participation. However, programs 
can be designed to involve men without requiring disclosure of HIV status. For example, an HIV 
prevention intervention implemented in the context of prenatal care that consisted of educational 
discussions and skills building around pregnancy, PMTCT, and HIV prevention and involved 
women who were living with HIV and women who were not, as well as their male partners, was 
not successful at increasing accurate disclosure of HIV status. Nevertheless, among couples 
randomized to the intervention group there was increased male HIV-testing, greater condom use, 
fewer women seroconverting, reduced IPV, greater adherence to HIV medication for infants, and 
fewer infant infections (Jones, Peltzer et al. 2013, Weiss, Peltzer et al. 2013). 
Multiple positive synergies may exist between stigma reduction, promotion of respectful 
maternity care, and male engagement. If self-stigma and community level stigma are reduced 
and dominant gender norms which support IPV challenged, women may feel safer disclosing 
HIV status to their male partners. Further, given that men object to HIV stigma and abuse of 
women during maternity care, reducing HIV-related stigma and discrimination and promoting 
respectful maternity care may also make services more welcoming for men (WHO 2012b: 11).
Research Questions
•	 What are the most promising interventions for engaging men in MCH and HIV care 










        




   
•	 How can pregnant and postpartum women and service providers enlist men as allies in 
promoting high quality maternity care and reducing HIV-related stigma and disrespect 
and abuse?
•	 What are the best models for involving male partners to support women’s health and 
promote their own health, while also ensuring that women’s autonomy, safety and 
choices are respected?
•	 Male involvement has been seen to improve PMTCT outcomes. Will male involvement 
also improve other outcomes, such as maternal morbidity and mortality? What are the 
pathways by which male involvement improves maternal health outcomes in the context 
of HIV?
Reduce HIV-Related Stigma and Discrimination and Promote Respectful
Maternity Care (RMC)
Efforts to reduce HIV-related stigma and discrimination and promote Respectful 
Maternity Care (RMC) are rooted in a human rights paradigm which defends the dignity of 
people living with HIV and of women during pregnancy and childbirth. HIV-related stigma and 
discrimination and disrespect and abuse discourage women from seeking health services and can 
cause them to drop-out of care (Bowser and Hill 2010, Ratcliffe 2013, Turan and Nyblade 2013). 
Anticipation of discrimination, internalized stigma, and having stigmatizing attitudes towards 
people living with HIV are associated with: refusing HIV testing in ANC, not returning for post-
test counseling, not delivering in a facility, reduced adherence to antiretroviral treatment for 
PMTCT, and not enrolling in HIV treatment services (Turan and Nyblade 2013). Similarly, 
despite expressing a preference for a facility-based delivery, many sub-Saharan African women 
choose to deliver at home because of previous experiences (their own or a relative’s/friend’s) of 
inadequate, low quality, and/or disrespectful care in facilities (Ratcliffe 2013). While 
intervention research on reduction of HIV-related stigma in the context of maternity care and 
RMC intervention research are still in their infancy, rights-based approaches to community 
mobilization and social support are promising (WHO 2011a, Yamin 2013).
Reducing HIV-related stigma and discrimination and promoting respectful maternity care 
will involve working at multiple levels: with individual women and healthcare providers, with 













Stangl et al. 2009, Ratcliffe 2013). Gender discrimination, stereotypes about HIV, and other 
sources of social vulnerability, such as class and ethnicity, frequently cause HIV-related stigma 
and discrimination and abuse of women during maternity care to be rendered invisible (Parker 
and Aggleton 2003, Bowser and Hill 2010). Challenging “business as usual” and creating 
awareness that many ubiquitous, taken-for-granted acts violate women’s rights and the rights of 
people living with HIV is crucial.  Embedding principles of non-discrimination and equality in 
national policy and legislative frameworks and facility-level “bills of rights” for patients, for 
example adoption of the White Ribbon Alliance’s Respectful Maternal Care Charter which 
describes the universal rights of childbearing women, can be important steps towards creating 
awareness and increasing accountability (Bustreo, Hunt et al. 2013, Yamin 2013). 
After a policy framework is established, steps must be taken to promote changes in 
service delivery. Healthcare provider training combined with participatory planning and quality 
improvement processes and community monitoring and evaluation are effective mechanisms for 
changing institutional practices. 
Healthcare worker training that combines information about HIV, skills-building, and 
contact with PLHIV improves knowledge about HIV and the importance of confidentiality and
universal precautions, and increases willingness to treat PLHIV (Brown, Macintyre et al. 2003). 
At the facility level, providing the means to implement universal precautions, conducting facility 
level research to identify stigma, involving all workers (not only healthcare providers) in 
planning to address stigma, and using participatory processes which include PLHIV are 
promising practices (Nyblade, Stangl et al. 2009). 
Monitoring and evaluation of HIV-related stigma and disrespect and abuse are also 
needed to promote institutional cultures of non-discrimination towards PLHIV and dignity 
during maternity care. Inclusion of validated RMC and stigma measures into quality 
improvement models would ensure that these issues are regularly evaluated as a central 
component of the day-to-day work of individuals and institutions. Some of the models that could 
be adapted to include measures of RMC and stigma are EngenderHealth’s Client-Oriented, 
Provider-Efficient Services, JHPIEGO’s Standards-Based Management and Recognition and 













•	 Do different interventions focused on reducing HIV-related stigma and discrimination 
and promoting Respectful Maternity Care (RMC) (for example healthcare provider 
training, patient rights charters, and quality improvement models) have an impact on 
rates of maternal morbidity and mortality, uptake of MCH or HIV services, retention in 
care, maternal and child health outcomes and quality of life measures?
Increase Community and Peer Support for Pregnant and Postpartum Women
Community monitoring and accountability mechanisms can generate political will for 
better service quality, demand for services, and improve health outcomes (Stoffregen, Andión et 
al. 2010, Barnes, Deshmukh et al. 2011). In the field of HIV, community program monitoring 
has been shown to increase the supply of PMTCT services while participatory approaches to 
generating local solutions and peer involvement increases demand for services among pregnant 
women (Ackerman Gulaid and Kiragu 2012). More broadly in the field of maternal and child 
health, participatory women’s groups that identified problems, developed locally-feasible plans 
to address the priority issues, implemented, and then assessed the results of their actions were 
shown to dramatically improve health outcomes (Prost, Colbourn et al. 2013). Meta-analysis of 
program results from seven randomized controlled trials in four countries found that women’s 
groups resulted in a 37% reduction of maternal mortality; if more than 30% of pregnant women 
in the community participated in a women’s group, the impact on women’s and children’s health 
was estimated to be even larger—55% reduction in maternal mortality and 33% reduction in 
neonatal deaths (Prost, Colbourn et al. 2013). The authors hypothesized that maternal mortality 
was reduced through improved uptake of ANC, better hygiene during and after delivery, and 
small changes in the rapidity of response and care-seeking which contributed to maternal 
survival (Prost, Colbourn et al. 2013). The Malawian study correlated establishing a women’s 
group in the community with a 74% reduction in the maternal mortality rate and a 28% reduction 
in the infant mortality rate (Lewycka, Mwansambo et al. 2013). 
Social support provided by peers has a long history in HIV treatment and care programs, 
and has been formalized in models such as Mothers to Mothers (M2M) and Mentor Mothers 












positive pregnant women participating in these programs have reported earlier and more frequent 
disclosure of HIV status and better psychosocial well-being (Baek, Mathambo et al. 2007) and 
have been more likely to bring infants for follow-up care (Futterman, Shea et al. 2010). Recently, 
a randomized cluster community trial in Malawi associated volunteer peer counseling with the 
community infant mortality rate falling 36% and overall infant morbidity falling 42% (Lewycka, 
Mwansambo et al. 2013). There is a need to determine how peer support interventions influence 
the uptake and use of services among pregnant and postpartum women, both those who are living 
with HIV and those who are not, and to evaluate impact on health outcomes. Data from a South 
African study suggests that antenatal and postpartum visits by trained peer mothers benefit 
women living with HIV and HIV-negative women. Women living with HIV who were visited by 
a peer mother were significantly less likely to have birth-related medical complications and more 
likely to administer infant antiretrovirals, practice exclusive infant feeding, and have infants with 
healthy height-for-age scores (le Roux, Tomlinson et al. 2013). Both women living with HIV and 
HIV-negative women who received visits from peer mothers during pregnancy and in the 
postpartum period were more likely to use condoms, breastfeed for longer, and exclusively 
breastfeed than women who did not receive this social support (le Roux, Tomlinson et al. 2013). 
Based on the disparate but overwhelmingly positive evidence for the impact of women’s 
groups and peer support scale-up and evaluation seem warranted. While information about the 
cost-effectiveness of such interventions is limited, a Malawian study reported that both 
participatory women’s groups and peer support during pregnancy and postpartum were highly 
cost-effective (Lewycka, Mwansambo et al. 2013). 
Research Questions
•	 Do the myriad programs which provide social support to women living with HIV in the 
context of PMTCT and postpartum:  i) increase safe disclosure of HIV status and/or ii) 
improve mental health postpartum and/or iii) improve antiretroviral adherence 
postpartum?
•	 How do different iterations of programs to provide social support for pregnant and 











•	 Do community monitoring and accountability mechanisms reduce maternal morbidity 



















Research Priority 3: Moving the Research and Evaluation Agenda Forward
Secondary Analysis
•	 Conduct retrospective, or prospective, ecological analysis in areas where prioritized 
interventions have sufficient coverage 
Improving the Evidence Base and Synergistic Knowledge Generation with Ongoing
Research or Programs 
•	 Include measures of disrespect and abuse during maternity care and HIV-related stigma 
and discrimination in models used for institutional quality improvement. 
•	 Promote and evaluate community engagement in data collection. Community 
involvement in data collection is an area which requires research and evaluation to 
establish how data quality and sustainability can be ensured and community generated 
results integrated into health information systems. While community involvement in data 
collection is not a panacea and requires significant planning and investments in 
supervision and support to ensure high quality data, it also has multiple advantages. First, 
it is feasible for community data collection to take place more frequently than traditional 
household surveys such as DHS or MICS, thereby providing information about the 
impact of interventions to improve maternal health at shorter intervals. Second, involving 
community members in data collection may provide both evidence and impetus for 
action, increasing accountability. Community involvement in data collection increases 
ownership of those involved and could be an important adjunct to the social support 
interventions mentioned as priorities for evaluation. The involvement of networks of 
women living with HIV and organizations that support women’s rights and health will be 
critical to such efforts. 
New Research
Evaluation of the socially transformative interventions described above would focus on 
proximate measures such as uptake and retention in HIV and MCH services, and effects on 
maternal health outcomes. Potential research designs include comparing outcomes before and 
after intervention and community cluster trials. Experts emphasized the need to extend
evaluation of interventions which aim to create an enabling environment for women beyond 
pregnancy and the immediate postpartum period, and to look between physical health outcomes 















Implications for Policy and Practice
The evidence presented in this document can be immediately useful for policy and 
practice. Some of the key take away messages are summarized below. 
Clinical Questions about Maternal Mortality and HIV
Women living with HIV in sub-Saharan Africa are six to eight times more likely to die 
during pregnancy and the immediate postpartum period than are HIV-negative women. To begin 
to address the intersections between HIV and maternal morbidity and mortality, there is an 
urgent need to ensure that the half of pregnant African women who aren’t currently learning their 
HIV status during pregnancy have an opportunity to do so. Several countries in the region have 
shown it is possible to reach 80% or more of women with HIV testing during pregnancy. To 
guide clinical practice and answer research questions about the relationships between HIV and 
maternal health, women must not only be tested, but test results must also be recorded and linked 
to other clinical and sociodemographic data in ways that are useful for making clinical and 
programmatic decisions. Clinical questions about how to treat women living with HIV during 
pregnancy and the postpartum period, and the impact that expanded access to ART will have on 
causes, rates, and distribution of maternal morbidity and mortality, need to be answered. 
To generate the needed information, vital registration and health information systems 
need to be strengthened. Cause of maternal death data must be improved, as must availability of 
facility-based information on pregnancy outcomes that includes HIV status, ART use, maternal 
morbidities and neonatal health. Implementation of the guidance for coding deaths during 
pregnancy, childbirth and puerperium (ICD-MM) promoted by the World Health Organization, 
wider use of autopsies and minimally invasive autopsies, improvement of verbal autopsy tools, 
and wider pharmacosurveillance which involves pregnant women will all contribute to 
improving the knowledge base. 
Integrating Health Service Delivery to Address Maternal Health and HIV
In general, efforts to integrate HIV testing and provision of ART with antenatal and 
postpartum care and to provide reproductive health services to women living with HIV have 
shown positive results. However, there is surprisingly little peer-reviewed research about 











prevention, and treatment of malaria and tuberculosis in environments that provide components 
of integrated MCH/HIV care. The literature shows that while service integration has had 
generally positive results, significant health systems challenges persist. Assessing and 
addressing human resource needs will be crucial for delivering high quality, integrated services. 
Task-shifting and job aids (such as checklists, mobile technologies etc.) show promise in some 
instances, but guidance is needed on the skills and staffing levels necessary to safely and 
effectively deliver critical services to pregnant and postpartum women living with HIV. The 
impact of service integration on medium-term health outcomes is generally not reported, and the 
influence of integrated HIV and MCH service delivery on maternal morbidity and mortality is 
unknown. 
Transforming the Social Context to Improve Maternal Health
A range of interventions that modify gender norms, reduce HIV-related stigma, mobilize 
communities to promote maternal health, and increase social support for pregnant and 
postpartum women have been shown to positively influence the policy context and demand for 
and delivery of PMTCT and maternal health services. There is also evidence that these 
interventions can improve service utilization, ART adherence and maternal health outcomes. The 
interventions prioritized for evaluation share a common mechanism of action: they seek to 
empower women using participatory methodologies and to change the social context by 
engaging the broader community to transform social norms that undermine women’s health. To 
overcome poor rates of uptake and retention in MCH and HIV services and improve adherence, 
adoption of interventions which promote an enabling environment for women to use health 
services should be routinely considered by policymakers and practitioners working in maternal 















Moving the Research Agenda Forward
Research and evaluation on maternal health and HIV can contribute to increased 
interaction between the maternal health and HIV communities. Integrating key outcomes 
measures and the variables needed to answer priority questions into routine program monitoring 
and collaborating on nested studies are places to begin.  Conducting joint research can provide a 
powerful impetus for dialogue, resulting in strengthened political constituencies and 
communities of practice. The investments being made to reduce maternal mortality and increase 
access to HIV treatment in sub-Saharan Africa are significant. The scope of these investments 
should be reflected in support for research and evaluation that fills priority knowledge gaps and 
assesses the impact of these investments on health outcomes. 
Priority Research Questions
While all of the knowledge gaps and research questions identified in this research agenda 
are important for reducing HIV-related maternal morbidity and mortality and improving health 
outcomes, the advisory working group prioritized the following research questions based on: 1) 
the immediate relevance for clinical practice or programs; 2) the expected public health benefits; 
and 3) the feasibility of conducting the research or evaluation in the short-term, particularly if it 
is possible to do so by improving existing monitoring and evaluation tools, strengthening data 
collection, conducting secondary analyses, or nesting research within on-going studies. 
Research Priority 1: Clinical Questions about Maternal Mortality and HIV
Greater accuracy and completeness of vital records is crucial for better ascertainment of 
causes of maternal death in women with HIV, and for tracking changes in health outcomes as 
ART availability is scaled-up. More research on cause of maternal death which uses autopsy and 
minimally invasive autopsy, and validates and improves verbal autopsy tools, is needed to 
generate better cause of maternal death data. 
Prospective observational evaluations of the rates and distribution of causes of maternal 
morbidity and mortality are needed to assess the impact of larger numbers of pregnant and 
postpartum women accessing and remaining on ART. Researchers with experience conducting 
prospective and retrospective analyses within HIV treatment cohorts and community-based 
longitudinal studies emphasized the need to allocate adequate resources to reduce the number of 












defined geographical area as ART access is scaled-up will provide compelling answers to 
questions about the relationship between HIV status, maternal morbidity, mortality, and access to 
ART. This cohort should include women living with HIV as well as those who are not, and 
women who attend facilities for delivery as well as those who give birth in the community. The 
need to track maternal deaths outside facilities will depend upon the proportion of women 
delivering in facilities in a given community or at the national level. Better identification of
causes of maternal death among women with HIV will allow the subsequent prioritization of 
causes of death to be addressed in clinical intervention studies. 
Research Priority 2: Integrating Health Service Delivery to Address Maternal Health and HIV
Successful delivery of integrated MCH and HIV services requires further health system 
strengthening. One crucial aspect is to identify and guarantee the needed mix of skills and 
staffing levels when implementing and evaluating integrated models of service delivery. More 
research and evaluation of integrated models that are already functioning to understand how HIV 
testing and treatment during antenatal, labor and delivery, and postpartum care can be delivered 
in ways that improve uptake, retention in services and linkage to antiretroviral treatment, and the 
effects on maternal morbidity and mortality is needed. Tuberculosis, unmet need for 
contraceptives, and in some settings, malaria, are important contributors to and causes of 
maternal deaths in sub-Saharan Africa, including among women with HIV. Thus, 
implementation research on how to successfully incorporate screening and treatment for 
tuberculosis and malaria, preconception counseling, and postpartum contraception within HIV 
and MCH services is called for. Disease burden, causes of maternal deaths at the community and 
country level, and the national policy context need to be considered when identifying which of 
the prioritized interventions will be the object of implementation science.   
Research Priority 3: Transforming the Social Context to Improve Maternal Health
There is an increasing body of compelling evidence about the social and psychosocial 
barriers women living with HIV face to seeking and remaining in MCH and HIV care, but there 
is less information available about how to overcome these barriers. Reducing HIV-related stigma 
and gender discrimination, including violence against women, increasing social support for 
pregnant and postpartum women, and mobilizing communities to promote respectful, high 













for women to access and remain in care. Engaging with men to support women’s health, 
especially during pregnancy and the postpartum period, is an urgent need. However,
interventions aiming to increase male involvement need to ensure autonomy and informed choice 
about disclosure to mitigate unintended negative consequences and promote the health and well-
being of women and men. Ideally, interventions that seek to create an enabling environment will 
address multiple social barriers to care and treatment simultaneously. Several of the interventions 
discussed have been seen to act synergistically, for example reducing both violence against 
women and HIV related stigma. The gender transformative interventions identified in this paper 
should be evaluated for their effects on proximate outcomes such as postpartum depression, 
antiretroviral adherence, and uptake and retention in health services, as well as HIV-related 
stigma, measures of social support and well-being, and health outcomes. 
Summary
Improving maternal health in the context of the sub-Saharan African HIV epidemic requires 
greater understanding of the relationships between HIV disease and maternal morbidity and 
mortality, integrated and effective responses by the health system, and a social context which 
promotes quality care and encourages use of MCH and HIV services. Advancing the proposed 
research agenda will make an invaluable contribution by generating needed evidence for policy 
and practice that improves the health of pregnant and postpartum women who are living with 
HIV, as well as those who are not. Collaborating on research which addresses HIV and maternal 
health and harmonizing aspects of program evaluation and routine monitoring is one way to raise 
awareness and catalyze the joint responses necessary to improve maternal health and eliminate 
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